Advertisement

Infection in Relation to Thoracic Transplantation

Abstract

Although the advent of focused and therefore superior immunosuppressive regimens has greatly decreased the incidence of infection in the thoracic transplant recipient, infection remains the leading cause of death in many centers[1]–[5]. Infection is acquired exogenously through usual nosocomial and community modes of transmission, and through transfusion, or is donor-transmitted. It can also result from endogenous reactivation of latent organisms within the recipient (Table 1).

Keywords

Transplant Recipient Renal Transplant Recipient Acquire Immune Deficiency Syndrome Cytomegalovirus Infection Human Immune Deficiency Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bourge RC, Naftel DC, Costanzo-Nordin MR et al. Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. J Heart Lung Transplant. 1993;12:549–62.PubMedGoogle Scholar
  2. 2.
    Kaye M. The Registry of the International Society for Heart and Lung Transplantation: tenth official report — 1993; J Heart Lung Transplant. 1993;12:541–8.PubMedGoogle Scholar
  3. 3.
    Chapparro C, Maurer J, Chamberlain D. Causes of death in lung transplant recipients. J Heart Lung Transplant. 1994;13:758–66.Google Scholar
  4. 4.
    Walley VM, Masters RG, Boone SA. et al. Analysis of deaths after heart transplantation: the University of Ottawa Heart Institute experience. J Heart Lung Transplant. 1993;12:790–801.PubMedGoogle Scholar
  5. 5.
    Bork J, Chinnock R, Ogata K et al. Infectious complications in infant heart transplantation. J Heart Lung Transplant 1993;12:S199–202PubMedGoogle Scholar
  6. 6.
    Rubin RH. Infection in the organ transplant recipient. In: Rubin R, Young L. editors. Clinical approach to infection in the compromised host, 3rd edn. New York: Plenum; 1994:629–705.Google Scholar
  7. 7.
    Verhoef J. Prevention of infections in the neutropenic patient. Clin Infect Dis. 1993(Suppl.2):S359–67.Google Scholar
  8. 8.
    Armstrong D. Protected environments are discomforting and expensive and do not offer meaningful protection. In: Brown AE, Armstrong D, editors. Infectious complications of neoplaslic diseases: Controversies in management. New York: York Medical Books. 1985:395–407.Google Scholar
  9. 9.
    Walsh TR, Guttendorf J, Dummer S. The value of protective isolation procedures in cardiac allograft recipients. Ann Thorac Surg. 1989;47:539–45.PubMedGoogle Scholar
  10. 10.
    Boyle EM, Burdine J, Bolman RM III, Successful treatment of Mycoplasma mediastinitis after heart-lung transplantation. J Heart Lung Transplant. 1993;12:508–12.PubMedGoogle Scholar
  11. 11.
    Counihan PJ, Yelland A, de Belder MA et al. Infective endocarditis in a heart transplant recipient. J Heart Lung Transplant. 1991;10:275–9.PubMedGoogle Scholar
  12. 12.
    Toporoff B, Rosado LJ, Appleton CP et al. Successful treatment of early infective endocarditis and mediastinitis in a heart transplant recipient. J Heart Lung Transplant. 1994;13:546–8.PubMedGoogle Scholar
  13. 13.
    Dajani AS, Bisno AL, Chung KJ et al, Prevention of bacterial endocarditis, Recommendations by the American Heart Association, J Am Med Assoc. 1990;264:2919.CrossRefGoogle Scholar
  14. 14.
    Dondero TJ, Rentorff RC, Mallison GF et al. An outbreak of legionnaire’s disease associated with a contaminated air-conditioning cooling tower, N Engl J Med. 1980;302:365–70.PubMedGoogle Scholar
  15. 15.
    Klaucke DK, Vogt R, LaRue D et al. Legionnaire’s disease: the epidemiology of two outbreaks in Burlington. Vermont, 1980. Am J Epidemiol. 1984;119:382–91.PubMedGoogle Scholar
  16. 16.
    Addiss D, Davis J, LaVenture M et al. Community-acquired legionnaire’s disease associated with a cooling tower: evidence for longer-distant transport of Legionella pneumophila. Am J Epidemiol. 1989;130:557–68.PubMedGoogle Scholar
  17. 17.
    Breiman RF, Cozen W, Fields BS et al. Role of air-sampling in an investigation of an outbreak of legionnaire’s disease associated with exposure to aerosols from an evaporative condenser. J Infect Dis. 1990;161:1257–61.PubMedGoogle Scholar
  18. 18.
    Garbe P, David B, Weisfeld J et al. Nosocomial legionnaire’s disease: epidemiologic demonstration of cooling towers as a source. J Am Med Assoc. 1985;254:521–4.CrossRefGoogle Scholar
  19. 19.
    Breiman RF, Fields BS, Sanden GN et al. Association of shower use with legionnaire’s disease. J Am Med Assoc. 1990;263:2924–6.CrossRefGoogle Scholar
  20. 20.
    Vogt RL, Hudson PJ, Orciari L et al. Legionnaire’s disease and a whirlpool spa. (Letter). Ann Intern Med. 1987;107:596.PubMedGoogle Scholar
  21. 21.
    Arnow PM, Chou T, Weil D et al. Nosocomial Legionnaire’s disease caused by aerosolized tap water from respiratory devices. J Infect Dis. 1982;146:460–77.PubMedGoogle Scholar
  22. 22.
    Mahoney FJ, Hoge CW, Farley TA et al. Communilywide outbreak of legionnaire’s disease associated with a grocery store mist machine. J Infect Dis. 1992;165:736–9.PubMedGoogle Scholar
  23. 23.
    Redd SC, Schuster DM, Quan J et al. Legionellosis in cardiac transplant recipients: results of a nationwide survey. (Letter) J Infect Dis. 1988;158:651–2.PubMedGoogle Scholar
  24. 24.
    Edelstein PH. Legionnaire’s disease. Clin Infect Dis. 1993;16:741–9.PubMedGoogle Scholar
  25. 25.
    Yu VL. Legionnaire’s disease: new understanding of community acquired pneummonia. Hosp Pract. 1993;28:63–7.Google Scholar
  26. 26.
    Kilborn JA, Manz LA, O’Brien M et al. Necrotizing cellulitis caused by Legionella micdudei. Am J Med. 1992;92:104–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Friedland L, Snydman DR, Weingarden AS et al. Ocular and pericardial involvement in legionnaire’s disease. Am J Med. 1984;77:1105–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Anaissie E, Kontoyiannis DP, Kantarjan H et al. Listeriosis in patients with CLL who were treated with fludarabine and prednisone. Ann Intern Med. 1992;117:466–8.PubMedGoogle Scholar
  29. 29.
    Galpin JE, editor. Listeriosis in normal and immunocompromised hosts. Infect Dis Alert. 1992;11:101–4.Google Scholar
  30. 30.
    Skogberg K, Syrjanen J, Jahkola M et al. Clinical presentation and outcome of listeriosis in patients with and without immunosuppressive therapy. Clin Infect Dis. 1992;14:815–21.PubMedGoogle Scholar
  31. 31.
    Nieman RE, Lorber B. Listeriosis in adults: a changing pattern. Report of eight cases and review of the literature 1968–1978. Rev Infect Dis. 1980;2:207–27.PubMedGoogle Scholar
  32. 32.
    Heck AF, Hameroff SB, Hornick RB. Chronic Listeria monocytogenes meningitis with normotensive hydrocephalus. Case report and review. Neurology [Minneap.] 1971;21:263–70.Google Scholar
  33. 33.
    Buchner LH, Schneierson S. Clinical and laboratory aspects of Listeria monocytogenes infections, with a report of ten cases. Am J Med. 1968;45:904–21.PubMedCrossRefGoogle Scholar
  34. 34.
    Spitzer PG, Hammer SM, Karchmer AW. Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. Rev Infect Dis. 1986;8:427–30.PubMedGoogle Scholar
  35. 35.
    Scheer MS, Hirschman SZ, Oral and ambulatory therapy of Listeria bacteremia and meningitis with trimethoprim-sulfamethoxazole. Mt Sinai J Med. 1982;49:411–14.PubMedGoogle Scholar
  36. 36.
    Hooper DC, Pruitt AA, Rubin RH. Central nervous system infections in the chronically immunosuppressed. Medicine [Baltimore]. 1982;61:166–88.Google Scholar
  37. 37.
    Schuchat A, Deaver KA, Wenger JD et al. Role of foods in sporadic lisleriosis. I. Case-control study of dietary risk factors. J Am Med Assoc. 1992;267:2041–5.CrossRefGoogle Scholar
  38. 38.
    Dromer C. Samer AMN, Velly JF et al. Tuberculosis in transplanted lungs. J Heart Lung Transplant. 1993;12:924–7.PubMedGoogle Scholar
  39. 39.
    Carlsen SE, Bergin CJ. Reactivation of tuberculosis in a donor lung after transplantation. AJR. 1990;154:495–7.PubMedGoogle Scholar
  40. 40.
    Higenbottam TW, Stewart S, Penketh AR et al. Transbronchial lung biopsy for the diagnosis of rejection in heart-lung transplant patients. Transplantation. 1988;46:532–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Trulock EP, Bolman RM, Genton R. Pulmonary disease caused by Mycobacterium chelonae in a heart-lung transplant recipient with obliterativc bronchiolilis. Am Rev Resp Dis. 1989;149:802–5.Google Scholar
  42. 42.
    Egan TM, Westcrman JH, Lambert CJ et al. Isolated lung transplantation for endstage lung disease: a viable therapy. Ann Thorac Surg. 1992;53:590–6.PubMedGoogle Scholar
  43. 43.
    Gentry LO, Zcluff B, Kiclhofner MA. Dermatologic manifestations of infectious diseases in cardiac transplant patients. [Review]. Infect Dis Clin N Am. 1994;8:637–54.Google Scholar
  44. 44.
    LcMense GP, Van Bakel AB, and Crumhley AJ III et al. Mycobacterium scrofulaceum infection presenting as lung nodules in a heart transplant recipient. Chest. 1994;106:1918–20.Google Scholar
  45. 45.
    Holzinger C, Laczkovics A, Imhof M et al. Tuberculosis of two cardiac allografts in one patient. Transplantation. 1994;57:1277–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Stephan JL, LeDiest F, Blanche S et al. Treatment of central nervous system B cell lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody. Transplantation. 1992;54:246–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Neeley SP, Denning DW. Cutaneous Mycobacterium thermoresistibile infection in a heart transplant recipient. Rev Infect Dis. 1989;11:608–11.PubMedGoogle Scholar
  48. 48.
    Tuder RM, Renya GS, Bensch K. Mycobacterial coronary artcritis in a heart transplant recipient. Human Pathol. 1986;17:1072–4.CrossRefGoogle Scholar
  49. 49.
    Novick RJ, Moreno-Cabral CE, Stinson EB et al. Nontuberculous mycobactenal infections in heart transplant recipients: a seventeen year experience. J Heart Transplant. 1990;9:357–63.PubMedGoogle Scholar
  50. 50.
    Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipients: report of 5 cases and review of the literature. Rev Infec Dis. 1983;5:216–26.Google Scholar
  51. 51.
    Lloveras J, Peterson PK, Simmons RL et al. Mycohacterial infections in renal transplant recipients. Seven cases and review of the literature. Arch Inlern Med. 1982;142:888–92.CrossRefGoogle Scholar
  52. 52.
    Riska H, Kulback B. Tuberculosis and kidney transplantation. Acta Med Scand. 1979;205:637–40.PubMedGoogle Scholar
  53. 53.
    Riska H, Gronhagen-Riska C, Ahoncn J. Tuberculosis and renal allograft transplantation. Transplant Proc. 1987;19:4096–7.PubMedGoogle Scholar
  54. 54.
    Ascher NL, Simmons RL, Marker S et al. Tuberculous joint disease in transplant patients. Am J Surg. 1978;135:853–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Daniels NJ, Dover JS, Schacter RK. Interaction between cyclosporin and rifampicin. Lancet. 1984;19:639.CrossRefGoogle Scholar
  56. 56.
    Langhoff E, Madsen S. Rapid metabolism of cyclosporin and prednisone in kidney transplant patient receiving tubcrcutostatic treatment. Lancet. 1983;29:1031.CrossRefGoogle Scholar
  57. 57.
    Modry DL, Stinson EB, Over PE et al. Acute rejection and massive cyclosporin requirements in heart transplant recipients treated with rifampin. Transplantation. 1985;39:313–14.PubMedCrossRefGoogle Scholar
  58. 58.
    Offerman G, Keller F, Molzahn M. Low cyclosporin A blood levels and acute graft rejection in a renal transplant recipient during rifampicin treatment. Am J Nephrol. 1985;5:385–7.Google Scholar
  59. 59.
    VanBuren D, Wideman CA, Ried M et al. The antagonistic effect of rifampicin upon cyclosporin bioavailability. Transplant Proc. 1984;16:1642–5.PubMedGoogle Scholar
  60. 61.
    Comstock GW, Woolpert SH. Prophylaxis. In: Schlossberg D. editor. Tuberculosis, 2nd edn. New York: Springer-Verlag; 1988:54–9.Google Scholar
  61. 62.
    Thomas PA Jr. Mozes MF, and Jonasson O. Hepatic dysfunction during isoniazid chemoprophylaxis in renal allograft recipients. Arch Surg. 1979;l14:597–9.Google Scholar
  62. 63.
    Higgins RSD, Kusne S, and Reyes J et al. Myeobacterium tuberculosis after liver transplantation: management and guidelines for prevention. Clin Transplant. 1992;6:81–90.Google Scholar
  63. 64.
    Alford R. Antimycobacterial agents. In: Mandell GL. Bennett JE. Dolin R. editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone: 1995;389–400.Google Scholar
  64. 65.
    Arduino RC, Johnson PC, Miranda AG. Nocardiosis in renal transplant recipients undergoing immunosuppression with cyclosporin. Clin Infect Dis. 1993;16:505–12.PubMedGoogle Scholar
  65. 66.
    Wilson JP, Turner HR, Kirchner KA et al. Nocardial infections in renal transplant recipients. Medicine [Baltimore]. 1989;68:38–57.Google Scholar
  66. 67.
    Simpson GL, Stinson EB, Egger MJ et al. Nocardial infections in the immunocompromised host: a detailed study in a defined population. Rev Infect Dis. 1981;3:492–508.PubMedGoogle Scholar
  67. 68.
    Beaman BL, Bumside J, Edwards B et al. Nocardia infections in the United States. 1972–1974. J Infect Dis. 1976;l34:286–9.Google Scholar
  68. 69.
    Kong NCT, Morad Z, Suleiman AB et al. Spectrum of nocardiosis in renal patients. Ann Acad Med. Singapore. 1990;19:375–9.PubMedGoogle Scholar
  69. 70.
    Leaker B, Hellyar A, Neild GH et al. Nocardia infection in a renal transplant unit. Transplant Proc. 1989;21:2103–4.PubMedGoogle Scholar
  70. 71.
    Krick JA, Stinson EB, Remington JS. Nocardia infection in heart transplant patients. Ann Intern Med. 1975;82:18–26.PubMedGoogle Scholar
  71. 72.
    Wallace RJ Jr. Septimus EJ, Williams TJ Jr et al. Use of trimethoprim-sulfamethoxazole for treatment of infections due to Nocardia. Rev Infect Dis. 1982;4:315–25.PubMedGoogle Scholar
  72. 73.
    Wallace RJ Jr. Steele LC, and Sumter G et al. Antimicrobial susceptibility patterns of Nocardia asteroides. Antimicrob Agents Chemother. 1988;32:1776–9.PubMedGoogle Scholar
  73. 74.
    Berkey P, Moore D, Rolston K. In vitro susceptibilities of Nocardia species to newer antimicrobial agents. Antimicrob Agents Chemother. 1988;32:1078–9.PubMedGoogle Scholar
  74. 75.
    Wallace RJ Jr. Nash DR, Johnson WK et al. B-Lactam resistance in Nocardia brasiliensis is mediated by B-lactamases and reversed in the presence of clavulanic acid. J Infect Dis. 1987;156:959–66.PubMedGoogle Scholar
  75. 76.
    Filice GA, Simpson GL. Management of Nocardia infections. In: Remington JS, Swartz MN, editors. Current clinical topics in infectious diseases, Vol. 5. New York: McGraw-Hill; 1984;49–64.Google Scholar
  76. 77.
    Segovia J, Pulpon LA, Crespo MG et al. Rhodococcus equi: first case in a heart transplant recipient. J Heart Lung Transplant. 1994;13:332–5.PubMedGoogle Scholar
  77. 78.
    Van Etta LL, Filice GS, Ferguson RM et al. Corynebacterium equi: a review of twelve cases of human infection. Rev Infect Dis. 1983;5:1012–18.PubMedGoogle Scholar
  78. 79.
    Harvey RL, Sunstrum JC. Rhodococcus equi infection in patients with and without human immune deficiency virus infection. Rev Infect Dis. 1991;84:1217–20.Google Scholar
  79. 80.
    Petersen LR, Mead RH, Perlroth MG. Unusual manifestations of secondary syphilis occurring after orthotopic liver transplantation. Am J Med. 1983;75:166–70.PubMedCrossRefGoogle Scholar
  80. 81.
    Gibel LJ, Sterling W, Hoy W et al. Is serological evidence of infection with syphilis a contraindication to kidney donation? Case report and review of the literature. J Urol. 1987;138:1226–7.PubMedGoogle Scholar
  81. 82.
    Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis. 1993;16:677–88.PubMedGoogle Scholar
  82. 83.
    Dummer JS, Bahnson HT, Griffith BP et al. Infections in patients on cyclosporine and prednisone following cardiac transplantation. Transplant Proc. 1983;15(Suppl. l.2):2779–8l.Google Scholar
  83. 84.
    Hofflin JM, Potasman I, Baldwin JC et al. Infectious complications in heart transplant recipients receiving cyclosporin and corticosteroids. Ann Intern Med. 1987;106:209–16.PubMedGoogle Scholar
  84. 85.
    Dummer JS, Montero CG, Griffith BP et al. Infections in heart-lung transplant recipients. Transplantation. 1986;41:725–9.PubMedCrossRefGoogle Scholar
  85. 86.
    Linder J. Infection as a complication of heart transplantation. J Heart Transplant. 1988;7:390–4.PubMedGoogle Scholar
  86. 87.
    Brooks RG, Hofflin JM, Jamieson SW et al. Infectious complications in heart-lung transplant recipients. Am J Med. 1985;79:412–22.PubMedCrossRefGoogle Scholar
  87. 88.
    Dauber JH, Paradis IL, Dummer JS et al. Infectious complications in pulmonary allograft recipients. Clin Chest Med. 1990;11:291–308.PubMedGoogle Scholar
  88. 89.
    Gentry LO, Zeluff BJ. Diagnosis and treatment of infection in cardiac transplant patients. Surg Clin N Am. 1986;66:459–65.PubMedGoogle Scholar
  89. 90.
    Rinaldi MG. Problems in the diagnosis of invasive fungal diseases. Rev Infect Dis. 1991;13:493–5.PubMedGoogle Scholar
  90. 91.
    Dowling RD, Baladi N, Zenati M et al. Disruption of the aortic anastomosis after heart-lung transplantation. Ann Thorac Surg. 1990;49:118–20.PubMedGoogle Scholar
  91. 92.
    Thomson D, Menkis A, Pflugfelder P et al. Mycotic aortic aneurysm after heart-lung transplantation. Transplantation. 1989;47:195–7.PubMedCrossRefGoogle Scholar
  92. 93.
    Anthuber M, Kemkes BM, Kreuzer E et al. Mediastinitis and mycotic aneurysm of the aorta after orthotopic heart transplantation. Tex Heart lnst J. 1991;18:186–93.Google Scholar
  93. 94.
    Fischman AJ, Alpert NM, Livni E et al. Pharmacokinetics of 18F-labeled fluconuzole in healthy human subjects by positron emission tomography. Antimicrob Agents Chemother. 1993;37:1270–7.PubMedGoogle Scholar
  94. 95.
    Fisher MA, Shen S-H, Haddad J et al. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother. 1989;33:1443–6.PubMedGoogle Scholar
  95. 96.
    Akova M, Akalin HE, Uzun O et al. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. (Letter) Eur J Clin Microbiol Infect Dis. 1991;10:598–9.PubMedCrossRefGoogle Scholar
  96. 97.
    Meunicr F. Prevention of mycoses in immunocompromised patients. Rev Infecl Dis. 1987;9:408–16.Google Scholar
  97. 98.
    Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845–51.PubMedGoogle Scholar
  98. 99.
    Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med. 1993;118:495–503.PubMedGoogle Scholar
  99. 100.
    Wingard JR, Merz WG, Rinaldi MG et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325:1274–7.PubMedGoogle Scholar
  100. 101.
    Hilton E, Isenberg HD, Alperstein P et al. Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for Candidal vaginitis. Ann Intern Med. 1992;116:353–7.PubMedGoogle Scholar
  101. 102.
    Weiland D, Ferguson RM, Peterson PK, et al. Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis, and management. Ann Surg. 1983;198:622–9.PubMedCrossRefGoogle Scholar
  102. 103.
    Gurwith MJ, Stinson EB, Remington JS. Aspergillus infection complicating cardiac transplantation. Arch Intern Med. 1971;128:541–5.PubMedCrossRefGoogle Scholar
  103. 104.
    Montero CG, Martinez AJ. Neuropathology of heart transplantation: 23 cases. Neurology. 1986;36:1149–54.PubMedGoogle Scholar
  104. 105.
    Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990;12:1147–1201.PubMedGoogle Scholar
  105. 106.
    Shamberger RC, Weinstein HJ, Grier HE et al. The surgical management of fungal pulmonary infections in children with acute myelogenous leukemia. J Pediatr Surg. 1985;20:840–4.PubMedCrossRefGoogle Scholar
  106. 107.
    Mayer J-M, Nimer L, Carroll K. Isolated aspergillar infection in cardiac transplant recipients: case report and review. Clin Infect Dis. 1992;15:698–700.PubMedGoogle Scholar
  107. 108.
    Bodey GP, Varvitarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis. 1989;148:230–8.Google Scholar
  108. 109.
    Meunier F. Fungal infections in the compromised host. In: Rubin RH, Young LS, editors. Clinical approach to infection in the compromised host, 2nd edn. New York: Plenum; 1988;193–216.Google Scholar
  109. 110.
    Arnow PM, Andersen RL, Mainous PD et al. Pulmonary aspergillosis during hospital renovation. Am Rev Resp Dis. 1978;118:49–53.PubMedGoogle Scholar
  110. 111.
    Kyriakides GK, Zinneman HH, Hall WH et al. Immunologic monitoring and aspergillosis in renal transplant patients. Am J Surg. 1976;131:246–52.PubMedCrossRefGoogle Scholar
  111. 112.
    Lentino JR, Rosenkranz MA, Michaels JA et al. Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road construction and contaminated air conditioners. Am J Epidemiol. 1982;116:430–7.PubMedGoogle Scholar
  112. 113.
    Meyers JD, Atkinson K. Infection in bone marrow transplantation. Clin Hematol. 1983;12:791–811.Google Scholar
  113. 114.
    Milliken ST, Powles RL. Antifungal prophylaxis in bone marrow transplantation. Rev Infect Dis. 1990;l2(Suppl.3):S374–9.Google Scholar
  114. 115.
    Winston DJ, Ho WG, Gale RP et al. Prophylaxis of infection in bone marrow transplants. Eur J Cancer Clin Oncol. 1988;24(Suppl. 1):S15–23.PubMedGoogle Scholar
  115. 116.
    Bennett JE, Dismukes WE, Duma RJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med. 1979;301,126–31.PubMedGoogle Scholar
  116. 117.
    Conti DJ, Tolkoff-Rubin NE, Baker GP Jr et al. Successful treatment of invasive fungal infection with fluconazole in organ transplant recipients. Transplantation. 1989;48:692–5.PubMedGoogle Scholar
  117. 118.
    Stevens D. Coccidioides immitis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th edn. New York: Churchill Livingstone; 1995;2365–75.Google Scholar
  118. 119.
    Brewer JH, Parrott CL, Rimland D. Disseminated coccidioidomycosis in a heart transplant patient. Sabouraudia. 1982;20:261–5.PubMedGoogle Scholar
  119. 120.
    Vartivarian SE, Coudron PE, Markowitz SM. Disseminated coccidioidomycosis. Unusual manifestations in a cardiac transplantation patient. Am J Med. 1987;83:949–52.PubMedCrossRefGoogle Scholar
  120. 121.
    Hall KA, Sethi GK, Rosado LJ et al. Coccidioidomycosis and heart transplantation. J Heart Lung Transplant. 1993;12:525–6.PubMedGoogle Scholar
  121. 122.
    Catanzaro A, Galgiani JN. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am J Med. 1995;98:249–56.PubMedCrossRefGoogle Scholar
  122. 123.
    Hyde L. Coccidioidal pulmonary cavitation. Dis Chest. 1968;54(Suppl. 1):273.PubMedGoogle Scholar
  123. 124.
    Goodwin RA Jr. Shapiro JL, Thurman GH et al. Disseminated histoplasmusis: clinical and pathological correlates. Medicine. 1980;59:1–32.PubMedCrossRefGoogle Scholar
  124. 125.
    Wheat LJ, Connolly-Stringfield PA, Baker RL et al Disseminated histoplasmosis in the acquired immunodeficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine [Baltimorc]. 1990;69:361–74.Google Scholar
  125. 126.
    Bullock WE. Histoplasma capsulatum. In: Mandell GL, Bennett JE, Dolin R. editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone; 1995;2340–53.Google Scholar
  126. 127.
    Wheat LJ. Systemic fungal infections: diagnosis and treatment. I. Hisloplasmosis. Infect Dis Clin N Am. 1988;2:841–59.Google Scholar
  127. 128.
    Wheat LJ, Kohler RB, Tewari RP. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med. 1986;314:83–9.PubMedGoogle Scholar
  128. 129.
    Davies SF. Serodiagnosis of histoplasmosis. In: Sarosi GA. editor. Seminars in respiratory infections. Orlando, FL: Grune & Stratton, 1986;1:9–15.Google Scholar
  129. 130.
    Goodwin RA, Loyd JE, des Prez RM. Histoplasmosis in normal hosts. Medicine. 1981;60:231–66.PubMedCrossRefGoogle Scholar
  130. 131.
    Wheat LJ, Hafner R, Wulfsohn M et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993;118:610–16.PubMedGoogle Scholar
  131. 132.
    Dismukes WE, Bradsher RW Jr. Cloud GC et al. Itraconazole therapy for blastomycosis and hisloplasmosis. Am J Med. 1992;93:489–97.PubMedCrossRefGoogle Scholar
  132. 133.
    Negroni R, Robles AM, Arechavala A et al. Keloconazole in the treatment of paracoccidioidomycosis and histoplasmosis. Rev Infect Dis. 1980;2:643–9.PubMedGoogle Scholar
  133. 134.
    Wheat LJ, Hafner RE, Ritchie M et al. Itraconazole is effective treatment for histoplasmosis in AIDS: prospective multicenter non-comparative trials. In: Proceedings of the 32nd ICAAC. Anaheim, CA; 1992; 312.Google Scholar
  134. 135.
    Deepe GS Jr. Bullock WE. Histoplasmosis: a granulomatous inflammatory response. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates, 2nd edn. New York: Raven Press: 1992:943.Google Scholar
  135. 136.
    Gomez FJ, Gomez AM, Deepe GS. An 80-kDalton antigen from Histoplasma capsulatum that has homology to heat-shock protein 70 induces cell-mediated immune responses and protection in mice. Infect Immun. 1992;60:2565–71.PubMedGoogle Scholar
  136. 137.
    Serody JS Mill MR, Detterbeck FC et al. Blastomycosis in transplant recipients: report of a case and review. Clin Infect Dis. 1993;16:54–8.PubMedGoogle Scholar
  137. 138.
    Butka BJ, Bennett SR, Johnson AC. Disseminated inoculation blastomycosis in a renal transplant recipient. Am Rev Resp Dis. 1984;130:1180–3.PubMedGoogle Scholar
  138. 139.
    Greene NB, Baughman RP, Kim CK et al. Failure of ketoconazole in a renal transplant patient with pulmonary blastomycosis. Chest. 1985;88:640–l.PubMedGoogle Scholar
  139. 140.
    Hii JH, Legault L, DeVeber G et al. Successful treatment of systemic blastomycosis with high-dose ketoconazole in a renal transplant recipient. Am J Kidney Dis. 1990;14:595–7.Google Scholar
  140. 141.
    Pechan WB, Novick AC, Lalli A et al. Pulmonary nodules in a renal transplant recipient. J Urol. 1980;124:11–14.Google Scholar
  141. 142.
    Winston DJ, Gale RP, Meyer DV et al. Infectious complications of human bone marrow transplantation. Medicine [Baltimore]. 1979;56:1–31.CrossRefGoogle Scholar
  142. 143.
    Restrepo A. Paracoccidioides brasiliensis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone; 1995;2386–9.Google Scholar
  143. 144.
    Sugar AM, Restrepo A, Stevens DA. Paracoccidioidomycosis in the immunosuppressed host. Report of a case and review of the literature. Am Rev Resp Dis. 1984;129:349–52.Google Scholar
  144. 145.
    Bennett JE. Miscellaneous fungi. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone; 1995;2389–93.Google Scholar
  145. 146.
    Alsip SG, Cobbs CG. Pseudoallescheria boydii infection of the central nervous system in a cardiac transplant recipient. South Med J. 1986;79:383–4.PubMedCrossRefGoogle Scholar
  146. 147.
    Winston DJ, Jordan MC, Rhoses J. Allescheria boydii infections in the immuno-suppressed host. Am J Med. 1977;63:830.PubMedCrossRefGoogle Scholar
  147. 148.
    Travis LB, Roberts GD, Wilson WR. Clinical significance of Pseudoallescheria boydii: a review of 10 years’ experience. Mayo Clin Proc 1985;60:531–7.PubMedGoogle Scholar
  148. 149.
    Kolbeck PC, Makhoul RG. Bollinger RR et al. Widely disseminated Cunninghamella muconmycosis in an adult renal transplant patient: case report and review of the literature. Am J Clin Pathol. 1975;64:544–8.Google Scholar
  149. 150.
    Myskowski PL, Brown AE, Dinsmore R et al. Mucormycosis following bone marrow transplantation. J Am Acad Dermatol. 1983;9:111–15.PubMedGoogle Scholar
  150. 151.
    Morduchowicz G, Schmueli D, Shapira Z et al. Rhinocerebral mucormycosis in renal transplant recipients: report of three cases and review of the literature. Rev Infect Dis. 1986;8:441–6.PubMedGoogle Scholar
  151. 152.
    Henriquez M, Levy R, Raja RM et al. Mucormycosis in a renal transplant recipient with a successful outcome. J Am Med Assoc. 1979;242:1397–9.CrossRefGoogle Scholar
  152. 153.
    Bribetz AR, Chuang MT, Burrows L et al. Rhizopus lung abscess in a renal transplant patient successfully treated by lobectomy. Chest. 1980;77:102–4.Google Scholar
  153. 154.
    Sugar A. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone; 1995;2311–21.Google Scholar
  154. 155.
    Fader RC, McGinnis MR. Infections caused by dematiaceous fungi: chromoblastomycosis and phaeohyphomycosis. Infect Dis Clin N Am. 1988;2:925–38.Google Scholar
  155. 156.
    Sudduth E, Crumbley AJ III, Farrar WE. Phaeohyphomycosis due to Exophiala species: clinical spectrum of disease in humans. Clin Infect Dis. 1992;15:639–44.PubMedGoogle Scholar
  156. 157.
    Haupt HM, Merz WG, Beschorncr WE et al. Colonization and infection with Trichosporon species in the immunosuppressed host. J Infect Dis. 1983;147:199.PubMedGoogle Scholar
  157. 158.
    Hoy H, Hsu KC, Rolston H et al. Trichosporon beigelii infection: a review. Rev Infect Dis. 1986;8:959–67.PubMedGoogle Scholar
  158. 159.
    Kim JH, Perfect JR. Infection and cyclosporin. Rev Infect Dis. 1989;11:677–90.PubMedGoogle Scholar
  159. 160.
    Kennedy MS, Deeg HJ, Siegel M et al. Acute renal toxicity with combined use of amphotericin B and cyclosporin after marrow transplantation. Transplantation. 1983;35:211–15.PubMedCrossRefGoogle Scholar
  160. 161.
    Heidemann HT, Gerkens J, Spickard WA et al. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med. 1983;75:476–81.PubMedCrossRefGoogle Scholar
  161. 162.
    Lopez-Berestein G. Liposomal amphotericin B in the treatment of fungal infections. Ann Intern Med. 1986;12:233–7.Google Scholar
  162. 163.
    Lopez-Berestein G, Bodey GP, Frankel LS et al. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol. 1987;5:310–17.PubMedGoogle Scholar
  163. 164.
    Weber RS, Lopez-Berestein G. Treatment of invasive aspergillosis sinusitis with liposomal-amphotericin B. Laryngoscope. 1987;97:937–41.PubMedCrossRefGoogle Scholar
  164. 165.
    Lopez-Berestein G, Bodey GP, Fainstein V et al. Treatment of systemic fungal infections with liposomal-ampholericin B. Arch Intern Med. 1989;149:2533–6.PubMedCrossRefGoogle Scholar
  165. 166.
    Patterson TF, Andriole VT. The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur J Cancer Clin Oncol. 1989;25(Suppl.2):S63–8.PubMedGoogle Scholar
  166. 167.
    Sculier JP, Bron D, Coune A et al. Successful treatment with liposomal amphotericin B in two patients with persisting fungemia. Eur J Clin Microbiol Infect Dis. 1989;8:903–7.PubMedCrossRefGoogle Scholar
  167. 168.
    Ringden O, Meunier F, Tollemar J et al. Efticacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother. 1991;28(Suppl.B):73–82.PubMedGoogle Scholar
  168. 169.
    Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Amtimicrob Chemother. 1991;28(Suppl.B):83–91.Google Scholar
  169. 170.
    Chopra R, Blair S, Strang J et al. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother. 1991;28(Suppl.B):93–104.PubMedGoogle Scholar
  170. 171.
    Katz NM, Pierce PF, Anzeck RA et al. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. J Heart Transplant. 1990;9:14–17.PubMedGoogle Scholar
  171. 172.
    Sugar AM, Saunders C, Idelson BA et al. Interaction of fluconazole and cyclosporin. Ann Intern Med. 1989;110:844.PubMedGoogle Scholar
  172. 173.
    Byrne WR, Wajszczuk CP. Cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS): successful treatment with fluconazole after failure of amphotericin B. Ann Intern Med. 1988;108:384–5.PubMedGoogle Scholar
  173. 174.
    Robinson PA, Knirsch AK, Joseph JA. Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis. 1990;12(Suppl.3):S349–63.PubMedGoogle Scholar
  174. 175.
    Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med. 1990;113:183–7.PubMedGoogle Scholar
  175. 176.
    Saag MS, Powderly WG, Cloud GA et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med. 1992;326:83–9.PubMedGoogle Scholar
  176. 177.
    Van Cutsem J, Van Gerven F, Janssen PAJ. Oral and parenteral therapy with saperconazole (R66905) of invasive aspergillosis in normal and immunocompromised animals. Antimicrob Agents Chemother. 1989;33:2063–8.PubMedGoogle Scholar
  177. 178.
    Denning DW, Hanson LH, Stevens DA. In vitro activity of saperconazole (R66905) compared with amphotericin B and itraconazole against Aspergillus species. Eur J Clin Microbiol Infect Dis. 1990;9:693–7.PubMedCrossRefGoogle Scholar
  178. 179.
    Ho M. Cytomegalovirus: biology and infection. In: Greenough WB. Merigan TC. editors. Current topics in infectious disease. New York: Plenum; 1982:20.Google Scholar
  179. 180.
    Pass RF, August AM, Dworsky M et al. Cytomegalovirus infection in a day care center. N Engl J Med. 1982;307:477–9.PubMedGoogle Scholar
  180. 181.
    Preiksaitis JK, Rosno S, Grumet C et al. Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy. J Infect Dis. 1983;147:974–81.PubMedGoogle Scholar
  181. 182.
    Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis. 1990;l2(Suppl.7):S754–66.Google Scholar
  182. 183.
    Betts RF, Freeman RB, Douglas RH Jr et al. Transmission of cytomegalovirus infection with renal allograft. Kidney Int. 1975;8:385–92.PubMedCrossRefGoogle Scholar
  183. 184.
    Singh N, Dummer JS, Kusne S et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis. 1988;158:124–31.PubMedGoogle Scholar
  184. 185.
    Dummer JS, Hardy A, Poorsattar A et al. Early infections in kidney, heart, and liver transplant recipients on cyclosporin. Transplantation. 1983;36:259–67.PubMedCrossRefGoogle Scholar
  185. 186.
    Cooper DK, Lanza RP, Oliver S et al. Infectious complications after heart transplantations. Thorax. 1983;38:822–8.PubMedGoogle Scholar
  186. 187.
    Burke CM, Glanville A, Macoviac M et al. The spectrum of CMV infection following human heart-lung transplantation. Chest. 1984;86:824–9.PubMedGoogle Scholar
  187. 188.
    Ho M. Cytomegalovirus: biology and infection, 2nd edn. New York: Plenum: 1991.Google Scholar
  188. 189.
    Chou S. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med. 1986;314:1418–23.PubMedGoogle Scholar
  189. 190.
    Chou S. Cytomegalovirus infection and reinfection transmitted by heart transplantation. J Infect Dis. 1987;155:1054–6.PubMedGoogle Scholar
  190. 191.
    Grundy JE, Lui S, Super M et al. Symptomatic cytomegalovirus infection in seropositive patients: reinfection with donor virus rather than reactivation of recipient virus. Lancet. 1988;2:132–5.PubMedCrossRefGoogle Scholar
  191. 192.
    Mach M, Stamminger TH, Jahn G. Human cytomegalovirus: recent aspects from molecular biology. J Gen Virol 1989;70:3117–46.PubMedGoogle Scholar
  192. 193.
    Fenner F, McAuslan BR, Mims CA et al., editors. The biology of animal viruses, 2nd edn. New York: Academic Press; 1974;452–8.Google Scholar
  193. 194.
    Stevens JG. Latent characteristics of selected herpesviruses. Adv Cancer Res. 1978;26:227–56.PubMedGoogle Scholar
  194. 195.
    Jordan MC. Latent infection and the elusive cytomegalovirus. Rev Infect Dis. 1983;5:205–16.PubMedGoogle Scholar
  195. 196.
    Ho M. Cytomegalovirus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone; 1995;1351–64.Google Scholar
  196. 197.
    Padgett BL, Walker DL, zuRhein GM et al. Cultivation of a papova-likc virus from human brain with progressive multifocal leukoencephalopathy. Lancet. 197l;l:1257–60.Google Scholar
  197. 198.
    Quinnan GV Jr. Kirmani N, Rook AH et al. Cytotoxic T cells in cylomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow transplant recipients. N Engl J Med. 1982;307:7–13.PubMedGoogle Scholar
  198. 199.
    Rook AH, Quinnan GV Jr. and Frederick WJ et al. Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients. Am J Med. 1984;76:385–92.PubMedCrossRefGoogle Scholar
  199. 200.
    Andreone PA, Olivari MT, Elick B et al. Reduction of infectious complications following heart transplantation with triple drug immunotherapy. J Heart Transplant. 1986;5:13–19.PubMedGoogle Scholar
  200. 201.
    Calhoon JH, Nichols L, Davis R et al. Single lung transplantation: factors in postoperative cytomegalovirus infection. J Thorac Cardiovasc Surg. 1992;l:21–6.Google Scholar
  201. 202.
    Rubin RH, Tolkoff-Rubin NE. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother. 1993,37:619–24.PubMedGoogle Scholar
  202. 203.
    Rubin RH. Infectious disease complications of renal transplantation. Kidney Int. 1993;44:221–36.PubMedCrossRefGoogle Scholar
  203. 204.
    Cheeseman SH, Rubin RH, Stewart JA et al. Controlled clinical trial of prophylactic human leukocyte interferon in renal transplantation. Effect on cytomegalovirus and herpes simplex virus infection. N Engl J Med. 1981;300:1345–49.CrossRefGoogle Scholar
  204. 205.
    Pass RF, Reynolds DW, Whelchel JD et al. Impaired lymphocyte transformation response to cytomegalovirus and phytohemagglutinin in recipients of renal transplants: association with antithymocyte globulin. J Infect Dis. 1981;143:259–65.PubMedGoogle Scholar
  205. 206.
    Marker SC, Howard RJ, Simmons RL et al. Cytomegalovirus infection: a quantitative prospective study of 320 consecutive renal transplants. Surgery. 1981;89:660–71.PubMedGoogle Scholar
  206. 207.
    Rubin RH, Cosimi AB, Hirsch MS et al. Effects of antithymocyle globulin on cytomcgalovirus infection in renal transplant recipients. Transplantation. 1981;31:143–5.PubMedCrossRefGoogle Scholar
  207. 208.
    Hibberd PL, Tolkhoff-Rubin NE, Cosimi AB et al. Symptomatic cytomegalovirus disease in the cytomegalovirus positive recipient treated with OKT3. Transplantation. 1992;53:68–72.PubMedCrossRefGoogle Scholar
  208. 209.
    Gonwa TA, Capehart JE, Pilcher JW et al. Cytomegalovirus myocarditis as a cause of cardiac dysfunction in a heart transplant recipient. Transplanlation. 1989;47:197–9.Google Scholar
  209. 210.
    Dummer JS, White L; Ho M et al. Morbidity of cytomegalovirus infection in heart or heart-lung transplants who received cyclosporin. J Infect Dis. 1985;152:1182–92.PubMedGoogle Scholar
  210. 211.
    Prieto M, Lake K, Pritzker M et al. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients. J Heart Lung Transplant. 1991;10:901–11.PubMedGoogle Scholar
  211. 212.
    Costanzo-Nordin MR, Swinnen LJ, Fisher SG et al. Cytomcgalovirus infections in heart transplant recipients: relationship to immunosuppression. J Heart Lung Transplant. 1992;11:837–46.PubMedGoogle Scholar
  212. 213.
    Lake KD, Anderson DJ, Milfred S et al. The incidence of cylomegalovirus disease in not increased after OKT3 induction therapy. (Letter) J Heart Lung Transplant. 1993;12:537–8.PubMedGoogle Scholar
  213. 214.
    Kirklin JK, Naftel DC, Levine TB et al. Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutiunal study. J Heart Lung Transplant. 1994;13:394–104.PubMedGoogle Scholar
  214. 215.
    Peterson PK, Balfour HH Jr. Marker SC et al. Cytomegalovirus disease in renal transplant allograft recipients: a prospective study of the clinical features, risk factors and impact of renal transplantation. Medicine [Baltimore]. 1980;59:283–300.Google Scholar
  215. 216.
    Maurer JR, Tullios DE, Scavuzzo M et al. Cytomegalovirus infection in isolated lung transplantations. J Heart Lung Transplant. 1991;10:647–9.PubMedGoogle Scholar
  216. 217.
    Duncan AJ, Dummer JS, Paradis IL et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant. 1991;10:638–16.PubMedGoogle Scholar
  217. 218.
    Gould FK, Freeman MB, Taylor CE et al. Prophylaxis and management of cylomegalovirus pneumonitis after lung transplantation: a review of experience in one center. J Heart Lung Transplant. 1993;12:695–9.PubMedGoogle Scholar
  218. 219.
    Mayoral JL, Loefller CM, Fasola CG et al. Diagnosis and treatment of cytomegalovirus disease in transplant patients bused on gastrointestinal tract manifestations. Arch Surg. 1991;126:202–6.PubMedGoogle Scholar
  219. 220.
    Fiala M, Chatterjee SN, Carson S et al. Cytomegalovirus retinitis secondary to chronic viremia in phagocytic leukocytes. Am J Ophthalmol. 1977;84:1977.Google Scholar
  220. 221.
    Murray HW, Knox DL, Green WR et al. Cytomegalovirus retinitis in adults: a manifestation of disseminated viral infection. Am J Med. 1977;63:574–84.PubMedCrossRefGoogle Scholar
  221. 222.
    Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med. 1993;119:924–35.PubMedGoogle Scholar
  222. 223.
    Van Thiel DH, Gavaler JS, Schode RR et al. Cytomegalovirus infection and gastric emptying. Transplantation. 1992;54:70–3.PubMedGoogle Scholar
  223. 224.
    Sakr M, Hassanein T, Gavaler J et al. Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation — incidence, location, and severity in cyclosporin-and FK506-treated patients. Transplantation. 1992;53:786–91.PubMedGoogle Scholar
  224. 225.
    Arabia F, Rosado LJ, Huston CL et al. Incidence and recurrence of gastrointestinal cytomegalovirus infection in heart transplantation. Ann Thorac Surg. 1993;55:8–11.PubMedGoogle Scholar
  225. 226.
    Sutherland DER, Chan FY, Foucar E et al. The bleeding cecal ulcer in transplant patients. Surgery. 1980;86:386–98.Google Scholar
  226. 227.
    Patel NP, Corry RJ. Cytomegalovirus as a cause of cecal ulcer with massive hemorrhage in a renal transplant recipient. Am Surg. 1980;46:260–2.PubMedGoogle Scholar
  227. 228.
    Kaplan CS, Petersen EA, Icenogle TB et al. Gastrointestinal cytomegalovirus infection in heart and heart-lung transplant recipients. Arch Intern Med. 1989;149:2095–100.PubMedCrossRefGoogle Scholar
  228. 229.
    Schulman LL, Reison DS, Austin JHM et al. Cytomegalovirus pneumonitis after cardiac transplantation. Arch Intern Med. 1991;151:1118–24.PubMedCrossRefGoogle Scholar
  229. 230.
    Okrent DG, Abraham E. Winston DJ. Cardiorespiratory patterns in viral septicemia. Am J Med. 1987;83:681–6.PubMedCrossRefGoogle Scholar
  230. 231.
    Sayage L, Gunby R, Gonwa T et al. Cytomcgalovirus endometritis after liver transplantation. Transplantation. 1990;49:815–18.PubMedCrossRefGoogle Scholar
  231. 232.
    Dorfman LJ. Cytomegalovirus encephalitis in adults. Neurology. 1973;23:136–43.PubMedGoogle Scholar
  232. 233.
    Spitzer PG, Tarsy D, Eliopulos GM. Acute transverse myelitis during disseminated cytomegalovirus infection in a renal transplant recipient. Transplantation. 1987;44:151–3.PubMedGoogle Scholar
  233. 234.
    Bale JF Jr. Human cytomegalovirus infection and disorders of the nervous system. Arch Neurol. 1984;41:310–20.PubMedGoogle Scholar
  234. 235.
    Minars N, Silverman JF, Escobar MR et al. Fatal cytomegalovirus inclusion disease: associated skin manifestations in a renal transplant patient. Arch Dermatol. 1977;113:1569–71.PubMedCrossRefGoogle Scholar
  235. 236.
    Schutze WP. Kirklin JK, Cummings OW et al. Cytomegalovirus hemorrhoiditis in cardiac allograft recipients. Transplantation. 1991;51:918–20.Google Scholar
  236. 237.
    Paya CV, Hermans PE, Wiesner RH et al. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis. 1989;160:752–8.PubMedGoogle Scholar
  237. 238.
    Shorr RI, Longo WL, Oberley TD et al. Cytomegalovirus-associated tubulointerstitial nephritis in an allogeneic bone marrow transplant recipient. Ann Intern Med. 1987;107:351–2.PubMedGoogle Scholar
  238. 239.
    McCarthy JM, McLoughlin MG, Shackleton CR et al. Cytomegalovirus epididymitis following renal transplantation. J Urol. 1991;146:417–19.PubMedGoogle Scholar
  239. 240.
    Min KW, Wickemeyer WJ, Chandran P et al. Fatal cytomegalovirus infection and coronary arterial thromboses after heart transplantation: a case report. J Heart Transplant. 1987;6:2100–5.Google Scholar
  240. 241.
    Chou S. Newer methods for diagnosis of cylomegalovirus infection. Rev Infect Dis. 1990;l2(Suppl.7):S727–36.Google Scholar
  241. 242.
    Farrell HE, Shellam GR. Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J Gen Virol. 1991;72:149–56.PubMedGoogle Scholar
  242. 243.
    Gleaves CA, Smith TF, Shuster EA et al. Comparison of standard tube and shell vial culture techniques for (he detection of cytomegalovirus in clinical specimens J Clin Microbiol. 1985;21:217–21.PubMedGoogle Scholar
  243. 244.
    Erice A, Holm MA, Gill PC et al. Cytomegalovirus (CMV) anligenemia assay is more sensitive than the shell vial cultures for rapid detection of CMV in polymorphonuclcar blood leukocytes. J Clin Microbiol. 1992;30.2822–5.PubMedGoogle Scholar
  244. 245.
    The TH, van der Ploeg M, and van der Berg AP et al. Direct detection of cytomegalovirus in peripheral blood leukocytes — a review of the antigenemia assay and polymerase chain reaction. Transplantation. 1992;54:193–8.PubMedCrossRefGoogle Scholar
  245. 246.
    van der Bij W, Forensma R, van Son WJ et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal staining of blood leucocytes. J Med Virol. 1988;25:179–88.PubMedCrossRefGoogle Scholar
  246. 247.
    van der Bij W, van Dyck RB, and van Son WJ et al. Antigen lest for early diagnosis of active cytomegalovirus infection in heart transplant recipients. J Heart Transplant. 1988;7:106–10.PubMedGoogle Scholar
  247. 248.
    van den Berg AP, van der Bij W, and van Son WJ et al. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal — transplantation — a report of 130 consecutive patients. Transplantation. 1989;48:991–5.PubMedCrossRefGoogle Scholar
  248. 249.
    van den Berg AP, Klompmaker IJ, Haagsma EB et al. Antigcnemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis. 1991;164:265–70.PubMedGoogle Scholar
  249. 250.
    van den Berg AP, Tegzess AM, and Scholten-Sampson A et al. Monitoring antigenemia is useful in guiding treatment of severe cytomegalovirus disease after organ transplantation. Transplant Int. 1992;5:101–7.CrossRefGoogle Scholar
  250. 251.
    Gerna G, Revello MG, Percivalle F. et al. Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different proteins. J Clin Microbiol. 1990;28:2681–8.PubMedGoogle Scholar
  251. 252.
    Miller H, Rossier E, Milk R et al. Prospective study of cytomegalovirus antigenemia in allograft recipients. J Clin Microbiol. 1991;29:1054–5.PubMedGoogle Scholar
  252. 253.
    Gerna G, Zipeto D, Parea M et al. Monitoring of human cytomegalovirus infection and ganciclovir treatment in heart transplant recipients by determination of viremia. antigenemia. and DNAemia. J Infect Dis. 1991;164:488–98.PubMedGoogle Scholar
  253. 254.
    Boland GJ, Verves C, Hene RJ et al. Early detection of primary cytomegalovirus infection after heart and kidney transplantation and the influence of hyperimmune globulin prophylaxis. Transplant Int. 1993;6:34–8.CrossRefGoogle Scholar
  254. 255.
    Kosleinen PK, Nieminen MS, Mattila SP et al. The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients Transplantation. 1993;55:547–55.Google Scholar
  255. 256.
    Crawford SW, Bowden RA, Hackman RC et al. Rapid detection of cytomegalovirus infection by bronchoalveolar lavage and centrifugation culture. Ann Intern Med. 1984;108:180–5.Google Scholar
  256. 257.
    Stockel E, Popow-Kraupp T, Heinz FX et al. Potential of in situ hybridization for early diagnosis of productive cytomegalovirus infection. J Clin Microbiol. 1988;26:2536–40.Google Scholar
  257. 258.
    Saiki RK, Scharf S, Faloona F et al. Enzymatic amplification of B-globulin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985;230:1350–4.PubMedCrossRefGoogle Scholar
  258. 259.
    Demmler GJ, Buffone GJ, Schimbor CM et al. Detection of cylomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J Infect Dis. 1988;158:1177–84.PubMedGoogle Scholar
  259. 260.
    Shibata D, Martin WJ, Applcman MD et al. Detection of cytomegalovirus DNA in peripheral blood of patients infected with human immunodeficiency virus. J Infect Dis. 1988;158:1185–92.PubMedGoogle Scholar
  260. 261.
    Bitsch A, Kirchner H, Dupke R et al. Cytomegalovirus transcripts in peripheral blood leukocytes of actively infected transplant patients detected by reverse transcription-polymerase chain reaction. J Infect Dis. 1993;167:740–3.PubMedGoogle Scholar
  261. 262.
    Duncan SR, Cook DJ. Survival of ganciclovir-treated heart transplant recipients with cytomegalovirus pneumonitis. Transplantation. 1991;52:910–13.PubMedCrossRefGoogle Scholar
  262. 263.
    Cooper DKC, Novitzky D. Schlegel V et al. Successful management of symptomatic cytomegalovirus disease with ganciclovir after heart transplantation. J Heart Lung Transplant. 1991;10:656–63.PubMedGoogle Scholar
  263. 264.
    Dunn DL, Mayoral JL, Gillingham KJ et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation. 1991;51:98–106.PubMedGoogle Scholar
  264. 265.
    Paya CV, Hermans PE, Smith TF et al. Efficacy of ganciclovir in liver and kidney transplant recipients with severe CMV infection. Transplantation. 1988;46:229–34.PubMedCrossRefGoogle Scholar
  265. 266.
    Harbison MA, De Giroliani PC, Jenkins RL et al. Ganciclovir therapy of severe cytomegalovirus infection in solid organ transplant recipients. Transplantation. 1988;46:82–8.PubMedCrossRefGoogle Scholar
  266. 267.
    Erice A, Jordan MC, Chace BA et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. J Am Med Assoc. 1987;257:3082–7.CrossRefGoogle Scholar
  267. 268.
    Watson FS, O’Connell JB, Amber IJ et al. Treatment of cytomegalovirus pneumonia in heart transplant recipients with 9(1.3-dihydroxy-2-propoxymethyl)-guanine (DHPG). J Heart Transplant. 1988;7:102–5.PubMedGoogle Scholar
  268. 269.
    Keay S, Petersen EA, Icenogle TB et al. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. Rev Infect Dis. 1988;10(Suppl.3):S563–72.PubMedGoogle Scholar
  269. 270.
    Icenogle TB, Petersen EA, Ray G et al. DHPG effectively treats CMV infection in heart and heart-lung transplant patients: a preliminary report. J Heart Transplant. 1987;6:199–203.PubMedGoogle Scholar
  270. 271.
    Reed EC, Bowden RA. Dandliker PS et al. Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis. 1987;156:641–5.PubMedGoogle Scholar
  271. 272.
    Reed EC, Bowden RA, Dandliker PS et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med. 1988;109:783–8.PubMedGoogle Scholar
  272. 273.
    Emanuel D, Cunningham I, Jules-Elysee K et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med. 1988;109:777–82.PubMedGoogle Scholar
  273. 274.
    Rubin RH, Wilson EJ, Barrett LV et al. The protective effects of hyperimmune anti-murine cytomegalovirus antiserum against lethal viral challenge: the case for passive-active immunization. Clin Immunol Immunopathol. 1986;39:151–8.PubMedCrossRefGoogle Scholar
  274. 275.
    Erice A, Chou S, Biron KK et al. Progressive disease due to ganciclovir resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 1989;320:289.PubMedGoogle Scholar
  275. 276.
    Locke TJ, Odom NS, Tapson JS et al. Successful treatment with trisodium phosphonoformate for primary cytomegalovirus infection after heart transplantation. J Heart Transplant. 1987;6:120–2.PubMedGoogle Scholar
  276. 277.
    Klintmalm G, Lonnqvist B, Oberg B et al. Intravenous foscamet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis. 1985;17:157–63.PubMedGoogle Scholar
  277. 278.
    Ludwin D, White N, Tsai S et al. Results of prospective matching for cytomegalovirus status in renal transplant recipients. Transplant Proc. 1987;19:3433–4.PubMedGoogle Scholar
  278. 279.
    Ackermann JR, LeFor WM, Weinstein S, et al. Four-year experience with exclusive use of cytomegalovirus antibody (CMV-Ab)-negative donors for CMV-Ab-negative kidney recipients. Transplant. Proc. 1988;1(Suppl. 1):469–71.Google Scholar
  279. 280.
    Wreghitt T. Cytomegalovirus in heart and heart-lung transplant recipients. J Antimicrob Chemother. 1989;23(Suppl.E):49–60.PubMedGoogle Scholar
  280. 281.
    Bowden RA, Sayers M, Flournoy N et al. Cytomegalovirus immunoglobulin and seronegative blood products to prevent primary cytomegalovirus infection after bone marrow transplant. N Engl J Med. 1986;314:1006–10.PubMedCrossRefGoogle Scholar
  281. 282.
    Adler SP, Chandrika T, Lawrence T et al. Cytomegalovirus infections in neonates acquired by blood transfusions. Pediatr Infect Dis. 1983;2:114–18.PubMedGoogle Scholar
  282. 283.
    Diosi P, Moldovan E, Tomescu N. Latent cytomegalovirus infection in blood donors. Br Med J. 1969;4:660–2.PubMedGoogle Scholar
  283. 284.
    Tegtmeier GE. Transfusion-transmitted cytomegalovirus infections: significance and control. Vox Sang. 1986;51(Suppl.):22–30.PubMedGoogle Scholar
  284. 285.
    Armstrong JA, Tarr GC, Youngblood LA et al. Cytomegalovirus infection in children undergoing open-heart surgery. Yale J Biol Med. 1975;49:83–91.Google Scholar
  285. 286.
    Preiksaitis JK, Brown L, Mackenzie M. The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J Infect Dis. 1988;157:523–9.PubMedGoogle Scholar
  286. 287.
    DeWitte T, Schattenberg A, van Dijk BA et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood bank donors. Transplantation. 1990;50:964–8.CrossRefGoogle Scholar
  287. 288.
    Sayers MH, Anderson KC, Goodnough LT et al. Reducing the risk for transfusion-transmitted cylomegalovirus infection. Ann Intern Med. 1992;116:55–62.PubMedGoogle Scholar
  288. 289.
    Lamberson HV Jr. McMillan JA, Weiner LB et al. Prevention of transfusion-associated cytomegalovirus (CMV) infection in neonates by screening blood donors for IgM to CMV. J Infect Dis. 1988;157:820–2.PubMedGoogle Scholar
  289. 290.
    Meyers JD, Leszczynski J, Zaia JA et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after bone marrow transplantation. Ann Intern Med. 1983;98:442–6.PubMedGoogle Scholar
  290. 291.
    Winston DJ, Pollard RB, Ho WG et al. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med. 1982;97:11–18.PubMedGoogle Scholar
  291. 292.
    Winston DJ, Ho WG, Cheng-Hsien L et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med. 1987;106:12–18.PubMedGoogle Scholar
  292. 293.
    Snydman DR, Werner BG, Heinze-Lacey B et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med. 1987;3127:1049–54.Google Scholar
  293. 294.
    Snydman DR, Werner BG, Tilney NL et al. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial. Transplant Proc. 1988;20:24–30.PubMedGoogle Scholar
  294. 295.
    Snydman DR. Review of the efficacy of cytomegalovirus immune globulin in the prophylaxis of CMV disease in renal transplant recipients. Transplant Proc. 1993;25(Suppl.4):25–6.PubMedGoogle Scholar
  295. 296.
    Melselaar HJ, Balk AHMM, and Mochtar B et al. Cytomegalovirus seronegative heart transplant recipients: prophylactic use of anti-CMV immunoglobulin. Chest. 1990;97:396–9.Google Scholar
  296. 297.
    Snydman DR, Werner BG, Dougherty NN et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. Ann Intern Med. 1993;19:984–91.Google Scholar
  297. 298.
    Saliba F, Arulnaden JL, Gugenheim J et al. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transplant Proc. 1989;21:2260–2.PubMedGoogle Scholar
  298. 299.
    Roy DM, Grundy JE, Evaluation of neutralizing antibody titers against human cytomegalovirus in intravenous gamma globulin preparations. Transplantation. 1992;54:1109–10.PubMedCrossRefGoogle Scholar
  299. 300.
    Gibert R, Habib R, Allard JP et al. Prevalence of CMV ELISA antibody: titer and neutralizing activity in intramuscular immune globulin of placental origin. Transplant Proc. 1988;20:24–30.Google Scholar
  300. 301.
    Emanuel D. Issues concerning the use of intravenous immunoglobulin for the immunoprophylaxis of cytomegalovirus infections in allogeneic bone marrow transplant recipients. Monogr Allergy (Karger, Basel). 1988;23:216–24.Google Scholar
  301. 302.
    Emanuel D, Peppard J, Chehimi J et al. The diagnostic, prophylactic, and therapeutic uses of monoclonal antibodies to human cytomegalovirus. Transplant Proc. 1987;l9(Suppl.7):132–7.Google Scholar
  302. 303.
    Chou S. Neutralizing antibody responses to reinfecting strains of cytomegalovirus in transplant recipients. J Infect Dis. 1989;160:16–21.PubMedGoogle Scholar
  303. 304.
    Tsevat J, Snydman DR, Pauker SG et al. Which renal transplant patients should receive cytomegalovirus immune globulin: a cost-effectiveness analysis. Transplantation. 1991;52:259–65.PubMedGoogle Scholar
  304. 305.
    Centers for Disease Control. Outbreak of hepatitis C associated with intravenous immunoglobulin administration — United States, October 1993–June 1994. Morbid Mortal Weekly Rep. 1994;43:505–9.Google Scholar
  305. 306.
    Brayman KL, Dafoe DC, Smythe WR et al. Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Arch Surg. 1988;123:1502–8.PubMedGoogle Scholar
  306. 307.
    Plotkin SA, Smiley ML, Friedman HM et al. Towne vaccine in the prevention of post-transplant CMV disease. Lancet. 1984;1:528–30.PubMedCrossRefGoogle Scholar
  307. 308.
    Plotkin SA, Starr SE, Friedman HM et al. Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis. 1990;12(Suppl.7):S827–38.PubMedGoogle Scholar
  308. 309.
    Plotkin SA, Starr SE, Friedman HM et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial. Ann Intern Med. 1991;114:525–31.PubMedGoogle Scholar
  309. 310.
    Balfour HH Jr. Welo PK, and Sach GW. Cytomegalovirus vaccine trial in 400 renal transplant candidates. Transplant Proc. 1985;17:81–3.Google Scholar
  310. 311.
    Spaete RR. A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc. 1991;23(Suppl.3):90–6.PubMedGoogle Scholar
  311. 312.
    Balfour HH Jr. Chace BA, and Stapleton JC et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med. 1989;320:1381–7.PubMedGoogle Scholar
  312. 313.
    Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118:179–84.PubMedGoogle Scholar
  313. 314.
    Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173–8.PubMedGoogle Scholar
  314. 315.
    Merigan TC, Reylund DG, Keay S et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 1992;326:1182–6.PubMedGoogle Scholar
  315. 316.
    Bailey TC, Trulock EP, Ettinger NA et al. Failure of prophylactic ganciclovir to prevent cytomcgalovirus disease in recipients of lung transplants. J Infect Dis. 1992;165:548–52.PubMedGoogle Scholar
  316. 317.
    Martin M, Manez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation. 1996 (In press).Google Scholar
  317. 318.
    Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplant. N Engl J Med. 1991;324:1005–11.PubMedGoogle Scholar
  318. 319.
    Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;235:1601–7.Google Scholar
  319. 320.
    Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med. 1991;324:1057–9.PubMedGoogle Scholar
  320. 321.
    Hibberd PL, Tolkhoff-Runin NE, Cosimi AB et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation. 1992;53:68–72.PubMedCrossRefGoogle Scholar
  321. 322.
    Hibberd PL, Tolkhoff-Rubin NE, Conti D et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. Ann Intern Med. 1995;123:18–26.PubMedGoogle Scholar
  322. 323.
    Simmons RL, Weil R, and Tallent MB et al. Do mild infections trigger the rejection of renal allografts? Transplant Proc. 1970;2:419–23.Google Scholar
  323. 324.
    Griffith BP, Paradis IL, Zeevi A et al. Immunologically mediated disease of the airways after pulmonary transplantation. Ann Surg. 1988;208:371–8.PubMedCrossRefGoogle Scholar
  324. 325.
    O’Grady JG, Alexander GJM, Sutherland S et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet. 1988;2:302–5.PubMedCrossRefGoogle Scholar
  325. 326.
    Paya CV, Hermans PE, Wiesner RH et al. Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis. 1989;160:752–8.PubMedGoogle Scholar
  326. 327.
    Fryd DS, Peterson PK, Ferguson RM et al. Cytomegalovirus as a risk factor in renal transplantation. Transplantation. 1980;30:436–9.PubMedCrossRefGoogle Scholar
  327. 328.
    Rubin RH, Tolkhoff-Rubin NE, Oliver D et al. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation. 1985;40:243–9.PubMedCrossRefGoogle Scholar
  328. 329.
    Grattan MT, Moreno-Cabral CE, Starnes VA et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. J Am Med Assoc. 1989;261:3561–6.CrossRefGoogle Scholar
  329. 330.
    Loebe M, Schuler S, Zais O et al. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Transplant. 1990;9:707–11.PubMedGoogle Scholar
  330. 331.
    Weimar W, Balk AH, Metselaar HJ et al. On the relation between cytomegalovirus infection and rejection after heart transplantation. Transplantation. 1991;52:162–4.PubMedGoogle Scholar
  331. 332.
    Normann SJ, Salomon DR, Leelachaikul P et al. Acute vascular rejection of the coronary arteries in human heart transplantation: pathology and correlations with immunosuppression and cylomegalovirus infection. J Heart Lung Transplant. 1991;10:674–87.PubMedGoogle Scholar
  332. 333.
    Koskinen PK, Niemenen MS, Krogerus LA et al. Cytomegalovirus infection and accelerated cardiac allograft va.sculopathy in human cardiac allografts. J Heart Lung Transplant. 1993;12:724–9.PubMedGoogle Scholar
  333. 334.
    Milne DS, Gascoigne A, Wilkes J et al. The immunohistopathology of obliterative bronchiolitis following lung transplantation. Transplantation. 1992;54:748–50.PubMedCrossRefGoogle Scholar
  334. 335.
    Reinsmoen NL, Bolman RM III, Savik K et al. Are multiple immunopathogenetic events occurring during the development of obliterative bronchiolitis and acute rejection? Transplantation. 1993;55:1040–4.PubMedGoogle Scholar
  335. 336.
    Nakleh RE, Bolman RM III, Henke CA et al. Lung transplant pathology. A comparative study of pulmonary acute rejection and cytomcgaloviral infection. Am J Surg Pathol. 1991;15:1197–1201.Google Scholar
  336. 337.
    Smiley ML, Mar EC. Huang ES. Cytomegalovirus infection and viral induced transformation of human endothelial cells. J Med Virol. 1988;21:3667–9.Google Scholar
  337. 338.
    Melnick JL, Adam E, DeBakey ME. Possible role of cytomegalovirus in atherogenesis. J Am Med Assoc. 1990;263:2204–7.CrossRefGoogle Scholar
  338. 339.
    Benditt EP, Barrett T, Dougall JK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci. 1983;80:6386–9.PubMedCrossRefGoogle Scholar
  339. 340.
    Fujinami RS, Nelson JA, Walker L et al. Sequence homology and immunologic cross-reactivity of human cytornegalovirus with HLA-DR beta-chain: a means for graft rejection and immunosuppression. J Virol. 1988;62:100–5.PubMedGoogle Scholar
  340. 341.
    Beck S, Barrel BG. Human cytomegalovirus incodes a glycoprotein homologous to MHC class-I antigens. Nature. 1988;331:269–72.PubMedCrossRefGoogle Scholar
  341. 342.
    Hosenpud JD, Chou S, Wagner CR. Cytomeglovirus-induced regulation of major histocompalibility complex Class I antigen expression in human aortic smooth muscle cells. Transplantation. 1991;52:896–903.PubMedCrossRefGoogle Scholar
  342. 343.
    Ross R. The pathogenesis of atherosclerosis — an update. N Engl J Med. 1986;314:488–500.PubMedGoogle Scholar
  343. 344.
    Saikku P, Leinonen M, Tenkanen L et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Intern Med. 1992;116:273–8.PubMedGoogle Scholar
  344. 345.
    Yamashiroya HM, Ghosh L. Yang R et al. Herpesviridae in the coronary arteries and aorta of young trauma victims. Am J Pathol. 1988;130:71–9.PubMedGoogle Scholar
  345. 346.
    Grundy JE, Downes KL. Up-regulation of LFA-3 and ICAM-I on the surfaces of fibroblasts infected with cytomegalovirus. Immunology. 1993;78:405–12.PubMedGoogle Scholar
  346. 347.
    Grundy JE. Virologic and pathogenetic aspects of cytomegalovirus infection. Rev Infect Dis. 1990 12(Suppl.3):S711–19.PubMedGoogle Scholar
  347. 348.
    Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. J Am Med Assoc. 1989;261:3607–9.CrossRefGoogle Scholar
  348. 349.
    Blanche G, Josien R, Douillard D et al. The influence of HLA A-B-DR matching on cytomegalovirus disease after renal transplantation. Transplantation. 1993;54:871–4.Google Scholar
  349. 350.
    Manez R, White LT, Linden P et al. The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation. Transplantation. 1993;55:1067–71.PubMedCrossRefGoogle Scholar
  350. 351.
    von Willebrand E, Lautenschlager I, Ahonen J. Cellular activation in the graft and in blood during CMV disease. Transplant Proc. 1989;21:2080–1.Google Scholar
  351. 352.
    van Dorp W, Jonges E, Bruggeman CA et al. Direct induction of MHC class I. but not class II, expression on endothelial cells by cytomegalovirus infection. Transplantation. 1989;48:469–72.PubMedCrossRefGoogle Scholar
  352. 353.
    Sedmark DD, Roberts WH, Stephens RE et al. Inability of cytomegalovirus infection of cultured endothelial cells to induce HLA class II antigen expression. Transplantation. 1990;49:458–62.CrossRefGoogle Scholar
  353. 354.
    Ustinov JA, Loginov RJ, Bruggeman CA et al. Cytomegalovirus induces class II expression in rat heart endothelial cells. J Heart Lung Transplant. 1993;12:644–51.PubMedGoogle Scholar
  354. 355.
    Skowronski EW, Mendoza A, Smith SC Jr. et al. Detection of cytomegalovirus in paraffin-embedded postmortem coronary artery specimens of heart transplant recipients by the polymerase chain reaction: implications of cytomegalov irus association with graft atherosclerosis. J Heart Lung Transplant. 1993;12:717–23.PubMedGoogle Scholar
  355. 356.
    Rinaldo CR Jr. Black PH, and Girsch MS. Interaction of cytomegalovirus with leukocytes from patients with mononucleosis due to cytomegalovirus. J Infect Dis. 1977;136:667–78.PubMedGoogle Scholar
  356. 357.
    Levin MJ, Rinaldo CR Jr. Leary PL et al. Immune response to herpesvirus antigens in adults with acute cytomegalovirai mononucleosis. J Infect Dis. 1979;140:851–7.PubMedGoogle Scholar
  357. 358.
    Carney WP, Hirsch MS. Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions. J Infect Dis. 1981;144:47–54.PubMedGoogle Scholar
  358. 359.
    Schrier RD, Rice GPA. Oldstone MBA. Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus. J Infect Dis. 1986;153:1084–91.PubMedGoogle Scholar
  359. 360.
    Dummer JS, Ho M, Rabin BP et al. The effect of cytomegalovirus and Epstein-Barr virus infection on T-lymphocyte subsets in cardiac transplant patients on cyclosporin. Transplantation. 1984;38;433–5.PubMedGoogle Scholar
  360. 361.
    Peterson PK, Balfour HH, Marker SC et al. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine [Baltimore]. 1980;59:283–300.Google Scholar
  361. 362.
    Rand KH, Pollard RB, Merigan TC. Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med. 1978;298:951–3.PubMedCrossRefGoogle Scholar
  362. 363.
    Gelmann EP, Clanton DJ, Jariwalla RJ et al. Characterization and location of myc homologous sequences in human cytomegalovirus DNA. Proc Natl Acad Sci USA. 1983;80:5107–11.PubMedCrossRefGoogle Scholar
  363. 364.
    Penn I. Kaposi’s sarcoma in renal transplant recipients. Transplantation. 1979;27:8–11.PubMedGoogle Scholar
  364. 365.
    Hanto DW, Frizzera G, Purtilo D. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein Barr virus. Cancer Res. 1981;41:4253–61.PubMedGoogle Scholar
  365. 366.
    Purtilo D, Saemundsen AK, Sakamoto K. Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res. 1981;41:4226–36.PubMedGoogle Scholar
  366. 367.
    Ho M, Miller G, Atchison RW. Epstein-Barr virus infections and DNA hybridization studies in post-transplantation lymphoma and lymphoproliferative lesions: the role for primary infection. J Infect Dis. 1985;152:876–86.PubMedGoogle Scholar
  367. 368.
    Ho M, Jaffe R, Miller G. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestation in children. Transplantation. 1988;45:719–27.PubMedCrossRefGoogle Scholar
  368. 369.
    Weintraub J, Warnke RA. Lymphoma in cardiac allotransplant recipients: clinical and histological features and immunologic phenotype. Transplantation. 1982;33:347–51.PubMedCrossRefGoogle Scholar
  369. 370.
    Bieber CP, Hebersling RL, Jamieson SW. Lymphoma in cardiac transplant recipients: association with the use of cyclosporin A, prednisone, and anti-thymocyte globulin. In: Purtilo DT, editor. Immune deficiency and cancer: Epstein-Barr virus and lymphoproliferative malignancies. New York: Plenum; 1984;309–20.Google Scholar
  370. 371.
    List AF, Greco FA, Vogler LB. Lymphoproliferative disease in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol. 1987;5:1673–89.PubMedGoogle Scholar
  371. 372.
    Straus SE, Cohen JI, Tosato G et al. Epstcin-Barr virus infection: biology, pathogenesis, and management. Ann Intern Med. 1993;118:45–58.PubMedGoogle Scholar
  372. 373.
    Stephaman E, Gruber SA, Dunn DL et al. Posttransplant lymphoproliferative disorders. Transplant Rev. 1991;5:120–9.CrossRefGoogle Scholar
  373. 374.
    Swinnen LJ, Costanzo-Nordin MR. Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med. 1990;323:1723–8.PubMedGoogle Scholar
  374. 375.
    Armitage JM, Kormos RL, Stuart RS et al. Posttransplant lymphoproliferativc disease in thoracic organ transplant patients: ten years of cyclosporin-based immunosuppression. J Heart Lung Transplant. 1991;10:877–87.PubMedGoogle Scholar
  375. 376.
    Emery RW, Lake KD. Post-transplantation lymphoproliferative disorder and OKT3. (Letter) N Engl J Med. 1991;324:1437.Google Scholar
  376. 377.
    Brouwer RML, Balk AHMM, Weimar W. Post-transplantation lymphoproliferative disorder and OKT3. (Letter) N Engl J Med. 1991;324:1437.Google Scholar
  377. 378.
    Cosimi AB, Rubin RH. Post-transplantation lymphoproliferative disorder and OKT3. (Letter) N Engl J Med. 1991;324:1438.Google Scholar
  378. 379.
    Fingeroth JD, Weiss JJ, Tedder TF et al. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA. 1984;81:4510–14.PubMedCrossRefGoogle Scholar
  379. 380.
    Frade R, Barel M, Ehlin-Eriksson B et al. gp l40, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc Natl Acad Sci USA. 1985;82:1490–3.PubMedCrossRefGoogle Scholar
  380. 381.
    Schooley RT. Epstein-Barr virus (infectious mononucleosis). In: Mandell GL, Bennett JE, Dolin R, editors: Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone: 1995;1364–77.Google Scholar
  381. 382.
    Diller J, Kallin B. The Epstein-Barr virus proteins. Adv Cancer Res. 1988;50:95–158.CrossRefGoogle Scholar
  382. 383.
    Sixbey JW, Nedrud JG, Raab-Traub N et al. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med. 1984;310:1225–30.PubMedGoogle Scholar
  383. 384.
    Preiksaitis JK, Diaz-Mitoma F, Mirzayans F et al. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis. 1992;166:986–94.PubMedGoogle Scholar
  384. 385.
    Sixbey JW, Shirley P, Sloas M et al. A transformation-incompetent, nuclear antigen 2-depleted Epstein-Barr virus associated with replicative infection. J Infect Dis. 1991;163:1008–15.PubMedGoogle Scholar
  385. 386.
    Sixbey JW, Shirley P, Chesney PJ et al. Detection of a second widespread strain of Epstein-Barr virus. Lancet. 1989;2:761–5.PubMedCrossRefGoogle Scholar
  386. 387.
    Randhawa PS, Jaffe R, Demetris AJ et al. Expression of Epstein-Barr virusencoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med. 1992;327:1710–14.PubMedCrossRefGoogle Scholar
  387. 388.
    Basgosz N, Hibberd PL, Tolkhoff-Rubin NE et al. Possible role of cytomegalovirus disease in the pathogencsis of post-transplant lymphoproliferative disorder. Abstract P-l-50, 12th Annual Meeting. American Society of Transplant Physicians. Houston. 1993.Google Scholar
  388. 389.
    Vieira P, DeWaal-Malefyt R, Dang MN et al. Isolation and expression of human eytokine inhibiting factor cDNA clones: homology to Epstein-Barr open-reading frame BCRF-I. Proc Natl Acad Sci USA. 1991;88:1172–6.PubMedCrossRefGoogle Scholar
  389. 390.
    Hanto DW, Gajl-Peczalska KJ, Frizzera G et al. Epstein-Barr virus (EBV)-induced polyclonal and monoclonal B cell lymphoproliferative diseases occurring after renal transplantation: clinical, pathologic, and virological findings and implications for therapy. Ann Surg. 1983;198:356–69.PubMedCrossRefGoogle Scholar
  390. 391.
    Ren KC, Chan SH. Possible enhancement of Epstein-Barr virus infections by the use of OKT3 in transplant recipients. Transplantation. 1988;45:988–9.PubMedGoogle Scholar
  391. 392.
    Cheeseman SH, Henle W, Ruhin RH et al. Epstein Barr virus infection in renal transplant recipients: Effects of anti-thymocyte globulin and interferon. Ann Intern Med. 1970;193:39–44.Google Scholar
  392. 393.
    Jones JF, Shurin S, Abramowsky C et al. T cell lymphomas containing Epstein-Barr viral DNS in patients with chronic Epstein-Barr virus infections. N Engl J Med. 1988;318:733–41.PubMedGoogle Scholar
  393. 394.
    Wiles HB, Laver J, Baum D. T cell lymphoma in a child after heart transplantation. J Heart Lung Transplant. 1994;13:1019–23.PubMedGoogle Scholar
  394. 395.
    Telenti A, Smith TF, Ludwig J et al. Epstein-Barr virus and persistent graft dysfunction after liver transplantation. Hepatology. 1991;14:282–6.PubMedGoogle Scholar
  395. 396.
    Hanto DW, Frizzera G. Gajl-Peczalska KJ. Epstein-Barr virus-induced B cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B cell proliferation. N Engl J Med 1982;306:913–18.PubMedCrossRefGoogle Scholar
  396. 397.
    Starzl TE, Porter KA, Iwatsuki S et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;17:583–7.CrossRefGoogle Scholar
  397. 398.
    Hanlo DW, Frizzera G, Gajl-Peczalska KJ et al. Acyclovir therapy of Epstein Barr virus induced post-transplant lymphoproliferative disease. Transplant Proc. 1985;17:89–93.Google Scholar
  398. 399.
    Sullivan JL, Byron KS, Brewsler FE et al. Treatment of life-threatening Epstein-Barr virus infection with acyclovir. Am J Med. 1982;73(Suppl.1A): 262–6.PubMedCrossRefGoogle Scholar
  399. 400.
    Pirsch JD, Stralta RJ, Sollinger HW et al. Treatment of severe Epstein-Barr virusinduced lymphoproliferative syndrome with gancielovir: two cases after solid organ transplantation. Am J Med. 1989;86:241–4.PubMedCrossRefGoogle Scholar
  400. 401.
    Blanche S, LeDiest F, Veber F et al. Treatment of severe Epstein-Barr virusinduced polyclonal B-lymphocyle proliferation by anti-B cell monoclonal antibodies: two cases after HLA-mismatched bone marrow transplantation. Ann Intern Med. 1988;108:199–203.PubMedGoogle Scholar
  401. 402.
    Fischer A, Blanche S, LeBidois J et al. Anti-B cell monoclonal antibodies in the treatment of severe B cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med. 1991;324:1451–6.PubMedGoogle Scholar
  402. 403.
    Shapiro RS, Chauvenet A, McGuire W et al. Treatment of B cell lymphoproliferative disorders with interfcron alfa and intravenous gamma globulin. (Letter) N Engl J Med. 1988;318:1334.PubMedCrossRefGoogle Scholar
  403. 404.
    Walker RC, Marshall WF, Strickler JG et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995;20:1346–53.PubMedGoogle Scholar
  404. 405.
    Douglas RG, Anderson S, Weg JG et al. Herpes simplex virus pneumonia: occurrence in an allotransplanted lung. J Am Med Assoc. 1969;210:902.CrossRefGoogle Scholar
  405. 406.
    Smyth RL, Higenbottam TW, Scott JP et al. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation. 1990;49:735–9.PubMedCrossRefGoogle Scholar
  406. 407.
    Straus SE, Smith HA, Brickman C et al. Acyclovir for chronic mucocutancous herpes simplex virus infection in immunosuppressed patients. Ann Intern Med. 1982;96:270–7.PubMedGoogle Scholar
  407. 408.
    Dummer JS, Armstrong J, Somers J et al. Transmission of infection with herpes simplex virus by renal transplantation. J Infect Dis. 1987;155:202–6.PubMedGoogle Scholar
  408. 409.
    Loxley RM, Flournoy N, Sullivan KM et al. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1986;6:1172–81.Google Scholar
  409. 410.
    Straus SE, Ostrove JM, Inchauspe G. Varicella-zoster virus infections: biology, natural history, treatment and prevention. Ann Intern Med. 1988;108:221–37.PubMedGoogle Scholar
  410. 411.
    Centers for Disease Control and Prevention Varicella-zoster immune globulin for the prevention of chickenpox. Recommendations of the immunization practices advisory committee. Ann Intern Med. 1984;100:859–65Google Scholar
  411. 412.
    Forghani B, Schmidt NJ, Dennis J. Antibody assays for varicella-zoster virus: Comparison of enzyme immunoassay with neutralization, immune adherence hemagglutination. and complement fixation. J Clin Microbiol 1978;8:545–52.PubMedGoogle Scholar
  412. 413.
    Feldhoff CM, Balfour HH Jr. and Simmons RL. et al. Varicella in children with renal transplants. J Pediatr. 1981;98:25–31.PubMedCrossRefGoogle Scholar
  413. 414.
    Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics. 1992;90:216–20.PubMedGoogle Scholar
  414. 415.
    Whitley RJ. Varicella zoster virus. In: Mandell GL, Bennett JK. Dolin R. editors. Principles and practice of infectious diseases. 4th edn. New York: Churchill Livingstone: 1995;1345–51.Google Scholar
  415. 416.
    Huff JC, Bean B, Balfour HH et al. Therapy of herpes zoster with oral acyclovir Am J Med. 1988;85:84–9.PubMedCrossRefGoogle Scholar
  416. 417.
    Wood MJ, Bean PH, McKendrick MW et al. Efficacy of oral acyclovir treatment of herpes zoster. Am J Med. 1988;85:79–83.PubMedGoogle Scholar
  417. 418.
    Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children: a collaborative study. J Pediatr 1982;101:622–5.PubMedCrossRefGoogle Scholar
  418. 419.
    Balfour HH Jr. Bean B, and Laskin OL et al. Acyclovir halts the progression of herpes zoster in immunocompromised patients. N Engl J Med. 1983;308:1448–53.PubMedCrossRefGoogle Scholar
  419. 420.
    Whitley RJ, Gnann JW. Acyclovir: a decade later. N Engl J Med. 1992;327:782–9.PubMedGoogle Scholar
  420. 421.
    Lusso P, Markham PD, Tschachler P et al. In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6). J Exp Med. 1988;167:1659–70.PubMedCrossRefGoogle Scholar
  421. 422.
    Wrzos H, Gibbons J, Abt PL et al. Human herpesvirus 6 in monocytes of transplant recipients. Lancet 1990;335:486–7.PubMedCrossRefGoogle Scholar
  422. 423.
    Brown NA, Sumaya CV, Liu CR et al. Fall in human herpersvirus 6 seropositivity with age. (Letter) Lancet. 1988;2:396.PubMedCrossRefGoogle Scholar
  423. 424.
    Efstathiou S, Gompels UA, Craxton MA et al. DNA homology between a novel human herpesvirus (HHV-6) and human cytomegalovirus. (Letter) Lancet 1988;1:63–4.PubMedCrossRefGoogle Scholar
  424. 425.
    Morris DJ, Littler E, Arrand JR et al Human herpesvirus-6 infection in renaltransplant recipients. N Engl J Med. 1989;320:1560–1.PubMedGoogle Scholar
  425. 426.
    Yamanishi K, Okuno T, Shiraki K et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet. 1988;1:1065–7.PubMedCrossRefGoogle Scholar
  426. 427.
    Krueger GRF. Human herpesvirus-6 infection and disease. (Letter) Lancet 1988;2:518.PubMedCrossRefGoogle Scholar
  427. 428.
    Spira TJ, Bozeinan LH, Sanderliu KC et al. Lack of correlation between human herpesvirus-6 infection and the course of human immunodeficiency virus infection. J Infect Dis. 1990;161:567–70.PubMedGoogle Scholar
  428. 429.
    Robinson WS. Hepadnaviridae: hepatitis B virus and hepatitis D virus. In: Mandell GL. Bennett JE, Dolin R. editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone: 1995;1406–39.Google Scholar
  429. 430.
    Katkov WN, Rubin RH. Liver disease in the organ transplant recipient: etiology, clinical impact, and clinical management. Transplant Rev. 1991;5:200–8.CrossRefGoogle Scholar
  430. 431.
    LaQuaglia MP, Tolkhoff-Rubin NE, Dienstag JL et al. Impact of hepatitis on renal transplantation. Transplantation. 1981;32:504–7.PubMedCrossRefGoogle Scholar
  431. 432.
    Alter MJ, Evatt BL, Margolis HS et al. Public health service interagency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of Hepatitis B and Hepatitis C. Morbid Mortal Weekly Rep. 1991;40(RR-4):1.Google Scholar
  432. 433.
    Szmuness W. Hepatocellular carcinoma and the hepatitis B virus, evidence for a causal association. Progr Med Virol. 1978;24:40.Google Scholar
  433. 434.
    Hollinger FB, Werch J, Melnick JL. A prospective study indicating that doubleantibody radioimmunoassay reduces the incidence of post-transfusion hepatitis B. N Engl J Med. 1974;290:1104–9.PubMedCrossRefGoogle Scholar
  434. 435.
    Alter HJ, Holland PV, Purcell RH. The emerging pattern of post-transfusion hepatitis. Am J Med Sci. 1975;270:329.Google Scholar
  435. 436.
    Hoofnagle JH, Seeff LB, Bales ZB et al. The Veterans Administration Cooperative Hepatitis Study Group. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med. 1978;298:1379–83.PubMedGoogle Scholar
  436. 437.
    Nagington J, Cossart YE, Cohen BJ. Reactivation of hepatitis B after transplantation operations. Lancet. 1977;1:558.PubMedCrossRefGoogle Scholar
  437. 438.
    Wands JR. Chura CM, Roll FJ et al. Serial studies of hepatitis associated antigen and antibody in patients receiving anti-tumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105.PubMedGoogle Scholar
  438. 439.
    Rao KV, Anderson RC. Long term results and complications in renal transplant recipients. Observations in the second decade. Transplantation. 1988;45:45–52.PubMedCrossRefGoogle Scholar
  439. 440.
    Rao KV, Kasiske BL, Anderson WR. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation. 1991;51:391–6.PubMedGoogle Scholar
  440. 441.
    Parfrey PS, Forbes RD, Hutchinson TA et al. The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation. 1984;37:461–6.PubMedCrossRefGoogle Scholar
  441. 442.
    Harnett JD, Zeldis JB, Parfrey PS et al. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation. 1987;44:369–76.PubMedCrossRefGoogle Scholar
  442. 443.
    Fauley CK, Mijch A, Gust ID et al. The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. Transplantation. 1991;52:497–500.Google Scholar
  443. 444.
    Dummer JS, Ho M, Simmons RL. Infections in solid organ transplant recipients. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th edn. New York: Churchill Livingstone; 1995;2722–32.Google Scholar
  444. 445.
    Perillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 1990;323:295–301.Google Scholar
  445. 446.
    Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet. 1991;1:813–15.CrossRefGoogle Scholar
  446. 447.
    Yu MC, Tong MJ. Coursaget P et al. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst. 1990;82: 1038–41.PubMedCrossRefGoogle Scholar
  447. 448.
    Pereira BJG, Milford EL, Kirkman RL et al. Transmission of hepatitis C by organ transplantation. N Engl J Med. 1991;325:454–60.PubMedGoogle Scholar
  448. 449.
    Pereira BJG, Milford EL, Kirkman RL et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med. 1992;327:910–15.PubMedGoogle Scholar
  449. 450.
    Roth D, Fernandez JA, Babischkin S et al. Detection of hepatitis C virus infection among cadaver organ donors: Evidence for low transmission of disease. Ann Intern Med. 1992;117:470–5.PubMedGoogle Scholar
  450. 451.
    Vincenti F, Lake J. Wright TP et al. Nontransmission of hepatitis C from cadaveric kidney donors to transplant recipients. Transplantation. 1993;55:674–5.PubMedGoogle Scholar
  451. 452.
    Diethelm AG, Roth D, Ferguson RM et al. Transmission of HCV by organ transplantation. (Letter). N Engl J Med. 1992;326:410–11.PubMedCrossRefGoogle Scholar
  452. 453.
    Pirsch JD, Belzer FO. Transmission of HCV by organ transplantation. (Letter) N Engl J Med. 1992;326:412.PubMedGoogle Scholar
  453. 454.
    Martinez E, Marcos A. Transmission of HCV by organ transplantation. (Letter) N Engl J Med. 1992;326:412.PubMedGoogle Scholar
  454. 455.
    Zeldis JB, Dienstag JL, Gale RP. Aplastic anemia and non-A, non-B hepatitis. Am J Med. 1983;74:64–8.PubMedCrossRefGoogle Scholar
  455. 456.
    Tzakis AG, Arditi M, Whitington PF et al. Aplastic anemia complicating orthotopic liver transplantation for non-A. non-B hepatitis. N Engl J Med. 1988;319:393–6.PubMedGoogle Scholar
  456. 457.
    Stock PG, Steiner ME, Freese D et al. Hepatitis-associated aplastic anemia after liver transplantation. Transplantation. 1987;43:595–7.PubMedCrossRefGoogle Scholar
  457. 458.
    Young NS. Flaviviruses and bone marrow failure. J Am Med Assoc. 1990;263:3065–8.CrossRefGoogle Scholar
  458. 459.
    Farci P, Alter HJ, Wong D et al. A long-term study of hepatitis C virus replication in non-A. non-B hepatitis. N Engl J Med. 1991;325:98–104.PubMedGoogle Scholar
  459. 460.
    Silva AE, Hosein B, Boyle RW et al. Diagnosis of chronic hepatitis C: comparison of imnuinoussays and the polymerase chain reaction. Am J Gastroenterol. 1994;89:493–6.PubMedGoogle Scholar
  460. 461.
    Lok ASF, Chien D, Choo Q-L et al. Antibody response to core, envelope, and nonstructural hepatitis C virus antigens: comparison ot immunocoinpetent and immunosuppressed patients Hepatology. 1993;18:497 502.PubMedCrossRefGoogle Scholar
  461. 462.
    Uyttendaele S, Claeys H, Mertens W et al. Evaluation of thirdgeneration screening and confirmatory assays for HCV-antibodies. Vox Sang. 1994;66:122–9.PubMedGoogle Scholar
  462. 463.
    Iwarson S, Norkrans G, Wejstal R. Hepatitis C: natural history of a unique infection. Clin Infect Dis. 1995;20:1361–70.PubMedGoogle Scholar
  463. 464.
    diBisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989,321:1506–10.Google Scholar
  464. 465.
    Shindo M, diBisceglie AM, Cheung L et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 1991;115:700–4.PubMedGoogle Scholar
  465. 466.
    Reichard O, Andersson J, Schvarez R et al. Ribavirin treatment tor chronic hepatitis C. Lancet. 1991;337:1058–61.PubMedCrossRefGoogle Scholar
  466. 467.
    diBisceglie AM, Shindo M, Fong T-L et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology. 1992;16:649–54.CrossRefGoogle Scholar
  467. 468.
    Chemello L, Cavalletto L, Bernardinello E et al. Randomized trial comparing interferon alfa or ribavirin alone or in combination for the treatment of chronic hepatitis C. In: VI International Symposium on Viral Hepatitis, February 1994, Madrid (abstract).Google Scholar
  468. 469.
    Prince AM, Brotman B, Huima T et al. Immunity in hepatitis C infection. J Infect Dis. 1992;165:438–43.PubMedGoogle Scholar
  469. 470.
    Farci P, Alter HJ, Govindarajan S et al. Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992;258:135–40.PubMedCrossRefGoogle Scholar
  470. 471.
    Keating MR, Wilhelm MP, Walker RC. Strategies for prevention of infection alter cardiac transplantation. Mayo Clin Proc. 1992;67:676–84.PubMedGoogle Scholar
  471. 472.
    Milfred SK, Lake KD, Anderson DJ et al. Practices of cardiothoracic transplant centers regarding hepatitis C seropositive candidates and donors. Transplantation. 1994;57:568–72.PubMedCrossRefGoogle Scholar
  472. 473.
    Lake KD, Milfred S. Reutzel T et al. Practices of cardiothoracic transplant centers regarding hepatitis C+ candidates and donors — a follow-up survey. J Heart Lung Transplant. 1995;14:570.Google Scholar
  473. 474.
    Wright TL, Hepatitis C and other forms of NANB hepatitis in transplantation. Presented at the North American Transplant Infectious Disease Symposium, Boston: 1993.Google Scholar
  474. 476.
    Kumar P, Pearson JE, Martin DH et al. Transmission of human immunodeficiency virus by transplant of a renal allograft with development of the acquired immunodeficiency syndrome. Ann Intern Med. 1987;106:244–5.PubMedGoogle Scholar
  475. 477.
    Milgrom M, Esquanazi V, Fuller L et al. AIDS in a transplant patient. Transplant Proc. 1985;17:75–6.Google Scholar
  476. 478.
    Bowen PA III, Lobel SA, Caruana RJ et al. Transmission of human immunodeficiency virus (HIV) by transplantation: clinical aspects and time course analysis of viral antigenemia and antibody production. Ann Intern Med. 1988;1046–8.Google Scholar
  477. 479.
    Carbone LG, Cohen DJ, Hardy MA et al. Determination of acquired immunodeficiency syndrome (AIDS) alter renal transplantation. Am J Kidney Dis. 1988;10:387–92.Google Scholar
  478. 480.
    Rubin RH, Jenkins RL, Byers WS Jr et al. The acquired immunodeficiency syndrome and transplantation. Transplantation. 1987;44:1–4.PubMedCrossRefGoogle Scholar
  479. 481.
    Bouscarat F, Samuel D, Simon S et al. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type I. Clin Infect Dis. 1994;19:854–9.PubMedGoogle Scholar
  480. 482.
    Ericc A, Rhame FS, Heussner RC et al. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis. 1991;13:537–47.Google Scholar
  481. 483.
    Dummer JS, Erb S, Breinig MK et al. Infection wilh human immunodeficiency virus in the Pittsburgh transplant population: a study of 583 donors and 1043 recipients. 1981–1986. Transplantation. 1989;47:134–40.PubMedCrossRefGoogle Scholar
  482. 484.
    Simonds RJ, Holmberg SD, Hurwitz RL et al. Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. N Engl J Med. 1992;326:726–32.PubMedCrossRefGoogle Scholar
  483. 485.
    Perez G, Ortiz-Interian C, Bourgoignic JJ et at, HIV-1 and HTLV-1 infection in renal transplant recipients. J AIDS. 1990;3:35–40.Google Scholar
  484. 486.
    Quarto M, Germinario C, Fontanu A et al. HIV transmission through kidney transplantation from a living related donor. (Letter) N Engl J Med. 1989;320:1754.PubMedGoogle Scholar
  485. 487.
    Imagawa DT, Lee MH, Wolinsky SM et al. Human immunodeficiency virus type I infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med. 1989;320:1458–62.PubMedGoogle Scholar
  486. 488.
    Wolinsky SM, Rinaldo CR, Kwok S et al. Human immunodeficiency virus type I (HIV-1) infection a median of 18 months before a diagnostic Western blot: evidence from a cohort of homosexual men. Ann Intern Med. 1989;111:961–72.PubMedGoogle Scholar
  487. 489.
    Larson CJ, Taswell HF, Human T cell leukemia virus type I (HTLV-I) and blood transfusion. Mayo Clin Proc. 1988;63:869–75.PubMedGoogle Scholar
  488. 490.
    Minamoto GY, Gold JWM, Scheinberg DA et al. Infection with human T cell leukemia virus type-I in patients with leukemia. N Engl J Med 1988;318:219–22.PubMedGoogle Scholar
  489. 491.
    Ratner L, Poiesz BJ, Leukemias associated wilh human T cell lymphotropic virus type I in a non-endemic region. Medicine (altimore). 1988;67:401–22.CrossRefGoogle Scholar
  490. 492.
    Wcinberg JB, Blazey DL, Janssen RS et al. Human T cell lymphotropic virus I and adult T cell leukemia: a report of a cluster in North Carolina. Am J Med 1988;85:51–8.CrossRefGoogle Scholar
  491. 493.
    Broder S, Pathogenic human retroviruses. (Editorial) N Engl J Med 1988;318:243–5.PubMedCrossRefGoogle Scholar
  492. 494.
    Quinn TC, Zacarias FK, and St John RK. HIV and HTLV I infections in the Americav a regional perspective. Medicine (Baltimore). 1989;68:189–208.Google Scholar
  493. 495.
    Hollsberg P, Hafler DA. Pathogenesis of disease induced by human lymphotropic virus type I infection. N Engl J Med. 1993;328: 1173–81.PubMedCrossRefGoogle Scholar
  494. 496.
    Gout O, Baulac M, Gessuin A et al. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Kngl J Med. 1990;322:383–8.CrossRefGoogle Scholar
  495. 497.
    Rosenblatt JD, Guide DW, Wachsman W et al. A second isolate of HTLV-I1 associated wilh atypical hairy-cell leukemia. N Engl J Med. 1986;315:372–7.PubMedCrossRefGoogle Scholar
  496. 498.
    Khabbaz RF, Onoralo IM, Cannon RO et al. Seroprevalence of HTLV-I and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med. 1992;326:375–9.PubMedGoogle Scholar
  497. 499.
    Demeter LM, JC, BK. and other polyomaviruses; progressive multitocal leukoencephalopathy. In: Mandell GL, Bennett JE, Dolin R. editors. Principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone; 1995;1400–6.Google Scholar
  498. 500.
    Flomenbaum MA, Jarcho JA, Schoen FJ. Progressive multifocal leukoencephalopathy fifty-seven months after heart transplantation. J Heart Lung Transplant. 1991;10:888–93.PubMedGoogle Scholar
  499. 501.
    Shields AF, Hackman RC, Fife KH et al. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med. 1985;312:529–33.PubMedGoogle Scholar
  500. 502.
    Myerowitz RL, Stalder H, Oxman MN et al. Fatal disseminated adenovirus infection in a renal transplant recipient. Am J Med. 1975;59:591–8.PubMedCrossRefGoogle Scholar
  501. 503.
    Landry ML, Fong CKY, Neddermann K. Disseminated adenovirus infection in an immunocumpromiscd host. Am J Med. 1987;83:555–9.PubMedCrossRefGoogle Scholar
  502. 504.
    Koneru B, Jaffe R, Esquivel CO et al. Adenoviral infections in pediatric liver transplant recipients. J Am Med Assoc. 1987;258:489–92.Google Scholar
  503. 505.
    Doud JR, Hinhamp T, Garrily ER Jr. Respiratory syncytial virus pneumonia in a lung transplant recipient: case report. J Heart Lung Transplant. 1992;l1:77–9.Google Scholar
  504. 506.
    Sinnott JT IV. Respiratory syncytial virus pneumonia in a cardiac transplant recipient. J Infect Dis. 1988;158:650–1.PubMedGoogle Scholar
  505. 507.
    Janner D, Bork J, Baum M et al. Severe pneumonia after heart transplantation as a resull of parvovirus B 19. J Heart Lung Transplant. 1994;13,336–8.PubMedGoogle Scholar
  506. 508.
    Frankel JK. Microbiology of Toxoplasma gondii. In: Hammond DH. Long PL. editors. Parasite life cycle and immunology. Baltimore, MD: University Park Press; 1973:343.Google Scholar
  507. 509.
    Shafer N. Toxoplasmosis. NY State J Med. 1975;75:1044–61.Google Scholar
  508. 510.
    Riemann HP, Meyer ME, Theiss JH et al. Toxoplasmosis in an infant fed unpastcurized goat’s milk. J Pediatr. 1975;87:573–6.PubMedCrossRefGoogle Scholar
  509. 511.
    Miller MJ, Aronson WJ, Remington JS. Late parasitemia in asymptomatic cases of acquired toxoplasmosis. Ann Intern Med. 1969;71:139–45.PubMedGoogle Scholar
  510. 512.
    Ruskin J, Remington JS. Toxoplasmosis in the compromised host. Ann Intern Med. 1976;84:193–9.PubMedGoogle Scholar
  511. 513.
    Anderson R, Sandberg T, Berglin E et al. Cytomegalovirus infections and toxoplasmosis in heart transplant recipients in Sweden. Scand J Infect Dis. 1992;24;411–17.Google Scholar
  512. 514.
    Waser M, Leonardi L, Mohasci P et al. Toxoplasmosis in the heart transplant patient. Ther Umseh. 1990;47:152–6.Google Scholar
  513. 515.
    Rubin RH, Tulkhoff-Rubin NE. Opportunistic infections in renal allograft recipients. Transplant Proc. 1988;20(Suppl.8): 12–18.PubMedGoogle Scholar
  514. 516.
    Molliman RH, Johnson JD, Adams S et al, Toxoplasmusis and heart transplantation. J Heart Lung Transplant. 1991;10:608–10.Google Scholar
  515. 517.
    Wreghitt TG, Gray JJ, Balfour AH. Tovoplasmosis in heart and heart and lung transplant recipients. J Clin Pathol. 1986;39:1135–9.PubMedCrossRefGoogle Scholar
  516. 518.
    Feldman H. Toxoplasmosis: an overview. Bull NY Acad Med. 1974;50:110–27.Google Scholar
  517. 519.
    Luft BJ, Naot Y, Araujo FG et al. Primary and reactivation Toxoplasma infection in patients with cardiac transplants: clinical spectrum and problems in diagnosis in a defined population. Ann Intern Med. 1983;99:27–31.PubMedGoogle Scholar
  518. 520.
    Shepp DH, Haekman RC, Conley FK et al. Toxoplasma gondii reactivation identified by detection of parasitemia in tissue culture. Ann Intern Med. 1985;103:218–21.PubMedGoogle Scholar
  519. 521.
    Beaman M, McCabe RE, Wong S-Y, Remington JS. Toxoplasma gondii. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th edn. New York: Churchill Livingstone; 2455–72.Google Scholar
  520. 522.
    Wagner FM, Reichenspurner H, Uberfuhr P et al. Toxoplasmosis after heart transplantation: diagnosis by endomyocardial biopsy. J Heart Lung Transplant. 1994;13:916–18.PubMedGoogle Scholar
  521. 523.
    Andreone PA, Olivari MT, Elick B et al. Reduction of infectious complications following heart transplantation with triple-drug immunolherapy. J Heart Lung Transplant. 1986;5:13–19.Google Scholar
  522. 524.
    LeClair RA. Transplantation pneumonia, associated with Pneumocystis carinii. among recipients of cardiac transplants. Am Rev Resp Dis. 1969;100:874–5.Google Scholar
  523. 525.
    Narins B, Jessup M. Pneumocystis carinii pneumonia after heart transplantation: a growing problem. J Heart Transplant. 1990;9:67.Google Scholar
  524. 526.
    Olsen SO, Renlund DG, O’Connell JB et al. Prevention of Pneumocystis pneumonia in cardiac transplant recipients by trimethoprim-sulfamethoxazole. Transplantation. 1993;56:359–62.PubMedCrossRefGoogle Scholar
  525. 527.
    Kramer MR, Stoehv C, Lewiston NJ et al. Trimethoprim-sulfamethoxazole prophylaxis for Pneutnocystis carinii infections in heart-lung and lung transplantation: how effective and for how long? Transplantation. 1992;53:586–9.PubMedCrossRefGoogle Scholar
  526. 528.
    Gryzan S, Paradis IL, Zeevi A et al. Unexpectedly high incidence of Pneumocystis carinii infection after lung-heart transplantation. Am Rev Resp Dis. 1988;137:1268–74.PubMedGoogle Scholar
  527. 529.
    Hughes WT, McNabb PC, Makres TD et al. Efficacy of trmethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonias. Antimicrob Agents Chcmother. 1974;5:289–93.Google Scholar
  528. 530.
    Hughes WT, Kuhn S, Chaudhary S. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297:1419–26.PubMedGoogle Scholar
  529. 531.
    Hughes WT, Rivera GK, Schell MJ et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316:1627–32.PubMedGoogle Scholar
  530. 532.
    Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. (Editorial) Arch Intern Med. 1995;155:1125–8.PubMedCrossRefGoogle Scholar
  531. 533.
    Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis. 1993;17(Suppl.2);S416–22.Google Scholar
  532. 534.
    Sepkowitz KA, Brown AE, Telzak AE et al. Pneumocystis carinii pneumonia among patients without AIDS in a cancer hospital. J Am Med Assoc. 1992;267:832–7.CrossRefGoogle Scholar
  533. 535.
    Graham BS, Tucker WS. Opportunistic infections in endogenous Cushing’s syndrome. Ann Intern Med. 1984;101:334–8.PubMedGoogle Scholar
  534. 536.
    Sanford JP, Sande MA, Gilbert DN et al. The Sanford Guide to HIV/AIDS Therapy. Dallas. TX: Antimicrobial Therapy Inc.: 1994;68–9.Google Scholar
  535. 537.
    Masur H, Gill VJ, Ognibene FP et al. Diagnosis of Pneumocystis pneumonia by induced sputum technique in patients without the acquired immunodeficiency syndrome. Ann Intern Med. 1988;109:755–6.PubMedGoogle Scholar
  536. 538.
    Kovacs JA, Ng VL, Masur H et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med. 1988;318:589–93.PubMedGoogle Scholar
  537. 539.
    While MJ. Prevention of infections in patients with neoplastic disease: use of a historical model for developmental strategies. Clin Infect Dis. 1993;17(Suppl.2):S359–67.Google Scholar
  538. 540.
    Genta RM. Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease. Rev Infect Dis. 1989;11:755–67.PubMedGoogle Scholar
  539. 541.
    Control of Chagas disease: report of a WHO expert committee. WHO Tech Rep Ser. 1991;811:27–37.Google Scholar
  540. 542.
    Schmunis GA. Trypanosoma cruzi, the etiologic agent of Chagas disease: status in the blood supply in endemic and non-endemic countries Transfusion. 1991;31:547–57.Google Scholar
  541. 543.
    Carrasco R, Miguel H, Camacho C et al. Prevalence of Trypanosoma cruzi infection in blood banks of seven departments of Bolivia. Mem Inst Oswaldo Cruz. 1990;85:69–73.PubMedGoogle Scholar
  542. 544.
    Kirchhoff LV. American trypanosomiasis (Chagas’ disease) a tropical disease now in the United States. N Engl J Med. 1993;329:639–44.PubMedCrossRefGoogle Scholar
  543. 545.
    Chocair PR, Amato Neto V, Sabbaga E et al. Aspectos clinicodiagnosticos relativos a fase aguda da doença de Chagas. em pacientes submetidos a transplante de rim e immunossuprimidos. Rev Soc Brasil Med Trop. 1985;18:43–5.Google Scholar
  544. 546.
    Gottcsdicner KM. Transplanted infections: donor-to-host transmission with the allograft. Ann Intern Med. 1989;110:1001–6.Google Scholar
  545. 547.
    Figueiredo JF, Martinez R, da Costa JC et al. Transmission of Chagits disease through renal transplantation: report of a case. Trans R Soc Trop Med Hyg. 1990;84:61–2.PubMedCrossRefGoogle Scholar
  546. 548.
    Landivar WHC, Nakasa T, Tachibana H et al. Seropositivity to Trypanosoma cruzi in blood donors in Santa Cruz. Bolivia. (Letter) J Infect Dis. 1992;166:1464–5.PubMedGoogle Scholar
  547. 549.
    Grant IH, Gold WJM, Winner M et al. Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med. 1989;111:849–51.PubMedGoogle Scholar
  548. 550.
    Geiseler PJ, Ito JI, Tegtmeier BR et al. Fulminant Chagas disease (CD) in bone marrow transplantation (BMT). In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. New York, 4–7 October 1987. Washington. DC: American Society for Microbiology: 1987;169 (abstract).Google Scholar
  549. 551.
    Nickerson P, Orr P, Schroeder M-L et al. Transfusion-associated Trypanosoma cruzi infection in a non-endemic area. Ann Intern Med. 1989;111:851–3.PubMedGoogle Scholar
  550. 552.
    Grant IH, Gold JW, Wittner M et al. Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med. 1989;11:849–51.Google Scholar
  551. 553.
    Stolf NA, Higushi L, Boechi E et al. Heart transplantation in patients with Chagas’ disease cardiomyopathy. J Heart Transplant. 1987;6:307–12.PubMedGoogle Scholar
  552. 554.
    Bocchi EA, Bellotti G, Uip D et al. Long-term follow-up after heart transplantation in Chagas’ disease. Transplant Proc. 1993;25:1329–30.PubMedGoogle Scholar
  553. 555.
    Libow LF, Beltrani VP, Silvers DN et al. Post-cardiac transplant reactivation of Chagas’ disease diagnosed by skin biopsy. Cutis. 1991;48:37–40.PubMedGoogle Scholar
  554. 556.
    Texeira ARL, Silva R, Cunha Neto E et al. Malignant non-Hodgkin’s lymphomas in Trypanosoma cruzi-infectcd rabbits treated with nitroarenes. J Comp Pathol. 1990;103:37–48.Google Scholar
  555. 557.
    Current WL, Reese NC, Ernst JV et al. Human cryptosporidiosis in inimunocompctent and immunodeficient persons: studies of an outbreak and experimental transmission. N Engl J Med. 1983;308:1252–7.PubMedGoogle Scholar
  556. 558.
    Cryptosporidiosis: assessment of chemotherapy of males with acquired immune deficiency syndrome (AIDS). Morbid Mortal Weekly Rep. 1982;31:589–92.Google Scholar
  557. 559.
    Black RE. Dykes AC. Sinclair SP et al. Giardiasis in day care centers: evidience of person-to-person transmission. Pediatrics. 1977;60:486–91.PubMedGoogle Scholar
  558. 560.
    Collier AC, Miller RA, Meyers JD. Cryptosporidiosis after marrow transplantation: Person-to-person transmission and treatment with spiramycin. Ann Intern Med. 1984;101:205–6.PubMedGoogle Scholar
  559. 561.
    Felman YM, Ricciardi NB. Sexually transmitted enteric diseases. Bull NY Acad Med. 1979;55:533–9.Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • K. Love

There are no affiliations available

Personalised recommendations